Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies (i.e., antibodies with generic names ending in \ximab\ or \zumab\, respectively) or fusion proteinsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.Xx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil/leucovorinXx_NEWLINE_xXKnown hypersensitivity to irinotecanXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXHistory of hypersensitivity to Chinese hamster ovary (CHO) cells or other human or humanized recombinant antibodies.Xx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXPatients with a known hypersensitivity to the combination/comparator agentXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of severe hypersensitivity reaction to monoclonal antibodies.Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor ELXx_NEWLINE_xXPatients must not have had history of severe toxicity and intolerance to or hypersensitivity to irinotecan or any other study drug; patients must not have had a severe infusion-related reaction during any prior therapy with pertuzumab or trastuzumabXx_NEWLINE_xXPatients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairsXx_NEWLINE_xXPatients must not have any history of hypersensitivity to any drugs or metabolites of midostaurinXx_NEWLINE_xXNo known history of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteinsXx_NEWLINE_xXNo known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the atezolizumab formulationXx_NEWLINE_xXAny previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatmentXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXNo history of hypersensitivity active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinibXx_NEWLINE_xXNo known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulationsXx_NEWLINE_xXPatients with known hypersensitivity to any TZD oral agents are not eligibleXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatinXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXNo history of severe hypersensitivity to a monoclonal antibodyXx_NEWLINE_xXThe patient must NOT have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitizationXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to any component of the formulation or substituted benzimidazolesXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.Xx_NEWLINE_xXKnown hypersensitivity to the trial drugs or other contraindication to standard “7+3” induction chemotherapyXx_NEWLINE_xXKnown intolerance to either of the study drugs (or any of the excipients)Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the components of the study drugXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib, temozolomide or any of the excipients of the productsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other mAbsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXPatients with a history of hypersensitivity to nickelXx_NEWLINE_xXPatients with known hypersensitivity to any component of the chemotherapy regimen will not be eligibleXx_NEWLINE_xXKnown hypersensitivity to gemcitabine, azacytidine or cytosine arabinosideXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanibXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXHistory of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments;Xx_NEWLINE_xXKnown hypersensitivity to any oligodeoxynucleotide.Xx_NEWLINE_xXHave severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorinXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXKnown prior severe hypersensitivity to the investigational products or any component in their formulations,Xx_NEWLINE_xXKnown prior severe hypersensitivity to platinum-related compounds for all cohorts, to pemetrexed for patients enrolled in Cohort A1, and to gemcitabine for patients enrolled in Cohort A2Xx_NEWLINE_xXHistory of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide or drugs with a similar chemical structure or class to these agentsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXHypersensitivity to nivolumab, ipilimumab, or any of their excipientsXx_NEWLINE_xXGrade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapyXx_NEWLINE_xXHas a known hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3) that could interfere with study endpoints or put patient safety at riskXx_NEWLINE_xXA history of hypersensitivity to other humanized monoclonal antibodies.Xx_NEWLINE_xXKnown hypersensitivity to any of the excipients of ribociclibXx_NEWLINE_xXPrior history of hypersensitivity, drug or radiation-induced, or other immune-mediated pneumonitisXx_NEWLINE_xXKnown hypersensitivity to any component of the atezolizumab or cobimetinib formulationsXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXDocumented progression on and/or intolerance/hypersensitivity to both paclitaxel and irinotecan (Part B only)Xx_NEWLINE_xXHistory of hypersensitivity to any of the additives in the alectinib drug formulationXx_NEWLINE_xXHistory of hypersensitivity reactions to study drug or any component of the study drug formulationXx_NEWLINE_xXHypersensitivity to pembrolizumab or history of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to carboplatin or cisplatinXx_NEWLINE_xXKnown hypersensitivity to Apatinib or components of the formulation.Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHypersensitivity to pembrolizumab or T-DM1 or any of their excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs.Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to any study drug componentXx_NEWLINE_xXPrior severe hypersensitivity reaction to another monoclonal antibody (mAb)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXSubject with a history of severe hypersensitivity reactions to any of the other excipients of the protocol IMPs (see Section 8.1.1);Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXCOHORT 1: Hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXCOHORT 2: Hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients with history of hypersensitivity to liposomal productsXx_NEWLINE_xXHypersensitivity to the active substance or to any of the excipientsXx_NEWLINE_xXHave a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drugXx_NEWLINE_xXHas had a severe hypersensitivity reaction to treatment with another monoclonal antibody.Xx_NEWLINE_xXPatient has history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).Xx_NEWLINE_xXKnown hypersensitivity to any component of required drugs in the studyXx_NEWLINE_xXKnown hypersensitivity to any of the components of RO6874281Xx_NEWLINE_xXFor Part B exclusively, known hypersensitivity to any of the components of trastuzumabXx_NEWLINE_xXFor Part C exclusively, known hypersensitivity to any of the components of cetuximabXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXPatients with a known hypersensitivity to the combination/comparator agentXx_NEWLINE_xXHas had a severe hypersensitivity reaction to treatment with another mAbXx_NEWLINE_xXHypersensitivity to taxanes (such as Steven Johnson syndrome). Hypersensitivity, such as rash < Grade 3 that is managed, is allowed.Xx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to carboplatinXx_NEWLINE_xXSevere hypersensitivity to other monoclonal antibodies (mAbs).Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of LEE011Xx_NEWLINE_xXHistory of severe hypersensitivity reaction (>= grade 3) to docetaxel, polysorbate 80 containing drugs, or any of the capsule components of enzalutamide, including Labrasol, butylated hydroxyanisole, and butylated hydroxytolueneXx_NEWLINE_xXPatient has a known hypersensitivity to ribociclib or any of its excipients, or prior treatment with CDK 4/6 inhibitorXx_NEWLINE_xXHistory of grade 3-4 immediate hypersensitivity reaction to paclitaxelXx_NEWLINE_xXHypersensitivity to:Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHistory of hypersensitivity to iodineXx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXPrevious severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXSubjects with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of CBL0137;Xx_NEWLINE_xXKnown hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipientsXx_NEWLINE_xXKnown hypersensitivity to sunitinib or masitinib or to any of the excipientsXx_NEWLINE_xXKnown hypersensitivity to afatinib, cisplatin, or pemetrexedXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXPatients who have had hypersensitivity to paclitaxel or any of its excipientsXx_NEWLINE_xXSubjects with a hypersensitivity to sirolimus.Xx_NEWLINE_xXHas a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients.Xx_NEWLINE_xXHas a known severe hypersensitivity (? Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.Xx_NEWLINE_xXPrevious severe hypersensitivity reaction to treatment with another monoclonal antibody.Xx_NEWLINE_xXHave previously participated in any study involving a checkpoint kinase 1 inhibitor or have hypersensitivity to the study drug or excipients.Xx_NEWLINE_xXHas severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipientsXx_NEWLINE_xXHas had a severe hypersensitivity reaction to treatment with a monoclonal antibody/components of the study treatment(s).Xx_NEWLINE_xXRefusal to potentially receive blood products and/or have a hypersensitivity to blood productsXx_NEWLINE_xXKnown hypersensitivity to any component of PVX-410, Hiltonol, Montanide, pembrolizumab, or excipientsXx_NEWLINE_xXKnown hypersensitivity to the components of niraparib components or their formulation excipientsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPrior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known hypersensitivity or contraindication to SC-005 or excipient contained in the drug formulation.Xx_NEWLINE_xXPreviously identified hypersensitivity to components of the formulations used in this studyXx_NEWLINE_xXHas severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to ipilimumab and/or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to exemestane or its excipientsXx_NEWLINE_xXHypersensitivity to nivolumab or any of its excipients.Xx_NEWLINE_xXHypersensitivity to NKTR-214 or any of its excipients.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.Xx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.Xx_NEWLINE_xXNo history of severe hypersensitivity reaction to Cremophor ELXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, or any component of the cobimetinib formulationXx_NEWLINE_xXParticipant has a known hypersensitivity to any of the excipients of H3B-6545.Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXAny history of a severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cellsXx_NEWLINE_xXKnown hypersensitivity to ferumoxytol or any of its componentsXx_NEWLINE_xXKnown intolerance to study drug (or any of the excipients) and/or known hypersensitivity to rapamycins (eg, sirolimus, everolimus, temsirolimus) or any of the excipientsXx_NEWLINE_xXKnown hypersensitivity to one or more of the study agents usedXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of ribociclib or everolimusXx_NEWLINE_xXKnown hypersensitivity to any study related agent excipient(s)Xx_NEWLINE_xXKnown hypersensitivity to platinum compoundsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotidesXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXThose with porphyria or with known hypersensitivity to porphyrins or porphyrin-like compoundsXx_NEWLINE_xXDocumented hypersensitivity reaction to any product with GSEXx_NEWLINE_xXHistory of allergic reactions or hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of, or known, hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system.Xx_NEWLINE_xXHistory of, or known, hypersensitivity to gemcitabine or platinum-containing compounds.Xx_NEWLINE_xXKnown hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.Xx_NEWLINE_xXEXCLUSION - TREATMENT: History of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXSubjects with known allergies, hypersensitivity, or intolerance to niraparib or its excipientsXx_NEWLINE_xXHistory of hypersensitivity to tremelimumab, durvalumab, or any excipientXx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of LEE011 or everolimusXx_NEWLINE_xXPrior hypersensitivity to any of the components of the study drugsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to cisplatin or vinblastine or other products of the same class;Xx_NEWLINE_xXKnown hypersensitivity to afatinib or the excipients of any of the trial drugsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXHistory of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.Xx_NEWLINE_xXHas had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAb).Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cellsXx_NEWLINE_xXAny known hypersensitivity or contraindication to the components of the study drug AZD1775Xx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXNo known hypersensitivity or contraindication to the components of study treatment (M6620 [VX-970], gemcitabine)Xx_NEWLINE_xXPatients with hypersensitivity to bortezomib, boron or mannitol.Xx_NEWLINE_xXCombination Arm: hypersensitivity to trastuzumabXx_NEWLINE_xXKnown hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red.Xx_NEWLINE_xXHas severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipientsXx_NEWLINE_xXSevere hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipientsXx_NEWLINE_xXAny known hypersensitivity or contraindication to the components of the study drug AZD1775Xx_NEWLINE_xXHistory of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodiesXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients with hypersensitivity to mTOR inhibitors or tamoxifen.Xx_NEWLINE_xXPatients may not have a history of allergic reaction or hypersensitivity to microcrystalline cellulose (Avicel PH302) or polysorbate 80 (Tween 80), which are components of the drug product MGCD516Xx_NEWLINE_xXKnown hypersensitivity or intolerance to metforminXx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies; any history of anaphylaxis or uncontrolled asthma.Xx_NEWLINE_xXHistory of severe hypersensitivity to study treatment excipients and additives or other monoclonal antibodies (mAbs) and/or their excipients.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXTREATMENT EXCLUSION: History of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXPorphyria or known hypersensitivity to Photofrin® or porphyrin-like compounds or to any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab, cobimetinib, or vemurafenib formulationsXx_NEWLINE_xXHistory of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulationXx_NEWLINE_xXHistory of hypersensitivity to sertralineXx_NEWLINE_xXPatients must not be known to have hypersensitivity to cisplatin, gemcitabine, or celecoxibXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its recipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXHistory of severe hypersensitivity reactions to monoclonal antibodies.Xx_NEWLINE_xXPatients with a known hypersensitivity to any excipient contained in the drug formulationXx_NEWLINE_xXAny history of hypersensitivity to irinotecanXx_NEWLINE_xXIs unable to receive any of the agents used in this study due a history of severe immediate hypersensitivity reaction (e.g. hypersensitivity to dimethyl sulfoxide (DMSO))Xx_NEWLINE_xXPreviously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.Xx_NEWLINE_xXHypersensitivity to any of the inactive ingredients (histidine, sucrose, polysorbate 80) or to other humanized monoclonal antibodies (mAbs)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to tremelimumab or any excipientXx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of INC280 (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXParticipants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)Xx_NEWLINE_xXPatients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)Xx_NEWLINE_xXHas a known hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPrior known hypersensitivity to any of the excipients of alpelisibXx_NEWLINE_xXKnown hypersensitivity to metforminXx_NEWLINE_xXHistory of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction.Xx_NEWLINE_xXNo history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXKnown hypersensitivity to immunoglobulins or to any other component of the IP formulationXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the MPDL3280A formulationXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatients with a history severe (>= grade 3) hypersensitivity reaction to a monoclonal antibody are ineligibleXx_NEWLINE_xXEXCLUSION CRITERIA FOR STRATUM C: Patients with a history severe (>= grade 3) hypersensitivity reaction to a monoclonal antibody are ineligibleXx_NEWLINE_xXKnown hypersensitivity to any of the components of cergutuzumab amunaleukin and atezolizumab; hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXParticipants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the excipientsXx_NEWLINE_xXKnown hypersensitivity to Velcade, boron, or mannitolXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXHave known hypersensitivity to platinum compounds or gemcitabine.Xx_NEWLINE_xXPatients with a known hypersensitivity to tacrolimus, methotrexate (Arm A or C) or MMF (Arm B or D)Xx_NEWLINE_xXKnown history, or suspected hypersensitivity to any excipients.Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to baker’s yeast, unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitizationXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXKnown hypersensitivity to the metal in the electrodes (stainless steel 304 L) that cannot be medically managedXx_NEWLINE_xXHistory of hypersensitivity to metformin or history of discontinuation secondary to attributed adverse effectsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXKnown hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator BrochureXx_NEWLINE_xXEXCLUSION - TREATMENT: History of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXGSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drug.Xx_NEWLINE_xXKnown or suspected hypersensitivity to 5-azacitidine or mannitolXx_NEWLINE_xXPart B only: Hypersensitivity to study drugs given in combination with LY3023414Xx_NEWLINE_xXKnown hypersensitivity to any of the components of the study drugsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHypersensitivity (history of allergic reactions) toXx_NEWLINE_xXHas a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dasatinibXx_NEWLINE_xXKnown hypersensitivity to methotrexateXx_NEWLINE_xXNo known hypersensitivity to trastuzumabXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXAny known hypersensitivity to bevacizumab, erlotinib or other excipients of these drugsXx_NEWLINE_xXPatients with a known hypersensitivity to treosulfan and/or fludarabineXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of M7824 or eribulin.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.Xx_NEWLINE_xXAUTOLOGOUS APHERESIS: History of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXTREATMENT WITH SJCAR19: History of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXKnown severe (grade >= 3 NCI-CTCAE) hypersensitivity reactions to monoclonal antibodies, or history of anaphylaxis.Xx_NEWLINE_xXKnown hypersensitivity to thalidomide.Xx_NEWLINE_xXEXCLUSION - PARTICIPANT: Participants with a history of hypersensitivity reactions to study agent or their excipients.Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to treatment with another monoclonal antibodyXx_NEWLINE_xXHas a history of hypersensitivity to durvalumab or tremelimumab excipientXx_NEWLINE_xXHypersensitivity to IV contrast; not suitable for pre-medicationXx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of bavituximab or pembrolizumab or monoclonal antibodyXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalanXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;Xx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXKnown hypersensitivity to bortezomib, ixazomib, dexamethasone, or ONC201Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas serious hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab, tremelimumab or any excipient.Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHypersensitivity to pembrolizumab or sunitinib or any of their excipientsXx_NEWLINE_xXHas hypersensitivity to pembrolizumab, epacadostat or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXThe patient has known hypersensitivity to gelatin or lactose monohydrateXx_NEWLINE_xXProven hypersensitivity to statinsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody.Xx_NEWLINE_xXKnown severe hypersensitivity to gemcitabineXx_NEWLINE_xXSubjects with a known hypersensitivity to olaparib or any of the excipients of the product.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of LMB-100 and/or SEL-110Xx_NEWLINE_xXHistory of anaphylactic reaction to a recombinant protein or hypersensitivity to PEGXx_NEWLINE_xXKnown allergies, hypersensitivity or intolerance to apalutamide, abiraterone acetate, prednisone, or GNRH agonist or GNRH antagonistXx_NEWLINE_xXHistory of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinibXx_NEWLINE_xXParticipants must not have hypersensitivity to nivolumab, urelumab, cabiralizumab or any of their excipientsXx_NEWLINE_xXPatients with hypersensitivity or other allergic reaction to taxanes.Xx_NEWLINE_xXHistory of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics or opioids.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agentXx_NEWLINE_xXHistory of hypersensitivity to cyclophosphamide, fludarabine, dimethyl sulfoxide (DMSO) or IL-2Xx_NEWLINE_xXHypersensitivity to pembrolizumab or lenvatinib or any of its excipientsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukinXx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHistory of hypersensitivity of osimertinib (or active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib)Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or analogsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] CTCAE v5.0 grade >= 3)Xx_NEWLINE_xXHas severe hypersensitivity (?Grade 3) to any study therapies including any excipientsXx_NEWLINE_xXHypersensitivity to Ipilimumab and/or nivolumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to gemcitabine (or other drug excipients) or chemically related drugs.Xx_NEWLINE_xXKnown hypersensitivity to the device constituent or TARIS Inserter materials.Xx_NEWLINE_xXPrior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or non-steroidal antiinflammatory drugs (NSAIDs)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas known hypersensitivity to either the drug substances or inactive ingredients in the drug productXx_NEWLINE_xXKnown hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity/intolerance to capecitabine, infusional 5-flurouracil, or bevacizumabXx_NEWLINE_xXHas severe hypersensitivity (>= grade 3) to pembrolizumab or any of its excipients.Xx_NEWLINE_xXGENERAL: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.Xx_NEWLINE_xXMEDICATION-RELATED: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.Xx_NEWLINE_xXSubject has known sensitivity and immediate hypersensitivity to any components of AMG 119 or conditioning regimen (cyclophosphamide and fludarabine).Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody.Xx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to erdafitinib or its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to components of the cobimetinib, atezolizumab, or pembrolizumab formulationsXx_NEWLINE_xXHas severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown prior or suspected hypersensitivity to investigational productsXx_NEWLINE_xXKnown intolerance or hypersensitivity to any of the products used in this study or their excipients.Xx_NEWLINE_xXKnown hypersensitivity to any component of study drug including potential subjects with a history of major immunologic reaction to any IgG-containing agentXx_NEWLINE_xXHistory of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agentsXx_NEWLINE_xXSubjects with known hypersensitivity to study drugs or their excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to another monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteinsXx_NEWLINE_xXAny history of a sever hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXPrevious hypersensitivity to rapamycin or rapamycin derivativesXx_NEWLINE_xXHypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipientsXx_NEWLINE_xXHistory of allergic reactions or hypersensitivity to the study drugs (hydroxychloroquine, gemcitabine, nab-paclitaxel, avelumab)Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodiesXx_NEWLINE_xXAny history of a sever hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compoundsXx_NEWLINE_xXHad a severe hypersensitivity reaction to treatment with pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or Chinese hamster ovary cell products.Xx_NEWLINE_xXHypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or its formulation excipientsXx_NEWLINE_xXPatient has a known history of hypersensitivity to defibrotide or any of the excipients.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXCarotid sinus hypersensitivity syndrome.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or paricalcitol or any of its excipients.Xx_NEWLINE_xXPatients who refuse to potentially receive blood products and/or have a hypersensitivity to blood productsXx_NEWLINE_xXHistory of clinical hypersensitivity to the immunotherapy proposed for combination treatment.Xx_NEWLINE_xXHas hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipientsXx_NEWLINE_xXHistory of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoidXx_NEWLINE_xXHas a known history of hypersensitivity to pembrolizumab or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of cabozantinib or nivolumabXx_NEWLINE_xXA history of sun hypersensitivity or photosensitive dermatitis.Xx_NEWLINE_xXParticipants with prior use of pirfenidone or known hypersensitivity to any of the components of study treatment will be excluded from the studyXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXSevere or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody (mAb) therapyXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody.Xx_NEWLINE_xXSevere hypersensitivity reactions to monoclonal antibodies, known hypersensitivity to the investigational medicinal products or to one or more of the excipients, autoimmune diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and live vaccines within 28 days prior to study entry.Xx_NEWLINE_xXHypersensitivity to ipilimumab or nivolumab or any of their excipientsXx_NEWLINE_xXPatients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components, capecitabine, fluorouracil (5-FU) and / or oxaliplatin are ineligibleXx_NEWLINE_xXKnown hypersensitivity to immunoglobulins or to any other component of the IP formulationXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipients.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipients.Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabineXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody including pembrolizumabXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to IP or comparator agentsXx_NEWLINE_xXHypersensitivity to PBZ or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to cetuximab or other EGFR antibodyXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its recipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXPatients with a known hypersensitivity to the olaparib, carboplatin or cabazitaxel.Xx_NEWLINE_xXHistory of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;Xx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to Vicinium or its componentsXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to gemcitabine or nab-paclitaxelXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas known hypersensitivity to baker's yeastXx_NEWLINE_xXHas severe hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas hypersensitivity to either study drug or any of the excipients.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this study; known sensitivity to busulfan or fludarabineXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHypersensitivity to nivolumab, ipilimumab, or any of its excipientsXx_NEWLINE_xXKnown prior severe hypersensitivity to investigational product(s) or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 4.03 grade >= 3).Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity to nivolumab, cyclophosphamide, fludarabine, interleukin-2, or any excipientXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to thyrotropin alpha (Thyrogen)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients must not have a known hypersensitivity to the components of niraparib or the excipientsXx_NEWLINE_xXHistory of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXHistory of hypersensitivity to the combination of durvalumab and tremelimumab.Xx_NEWLINE_xXHypersensitivity to nivolumab or ipilimumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatients with known hypersensitivity to perflutrenXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas known hypersensitivity to pembrolizumab and/or epacadostat or any of their excipientsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide, aldesleukin, or fludarabineXx_NEWLINE_xXA known hypersensitivity to any of the test materials or related compounds including murine and bovine products;Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to Avidin or AvidinOX (e.g. hen egg)Xx_NEWLINE_xXKnown hypersensitivity to ST2210 (DOTA biotin) or any excipient.Xx_NEWLINE_xXKnown hypersensitivity to BGB324, pembrolizumab, or any of their excipients.Xx_NEWLINE_xXKnown prior hypersensitivity to the investigational product or any component formulations, including known severe hypersensitivity reactions to monoclonal antibodiesXx_NEWLINE_xXKnown hypersensitivity to pirfenidone, carboplatin, pemetrexed or paclitaxelXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to IGF or methotrexate.Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xX(Atezolizumab-related exclusion) History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xX(Bevacizumab-related exclusion) Known hypersensitivity to any component of bevacizumabXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of severe hypersensitivity reaction to Cremaphor ELXx_NEWLINE_xXNo history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody and/or to study drug componentsXx_NEWLINE_xXHypersensitivity to ibrutinib or pembrolizumab or any of their excipientsXx_NEWLINE_xXSevere hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXPrior history of hypersensitivity to gemcitabine.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or tremelimumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to the combination or comparator agent (if applicable)Xx_NEWLINE_xXPatient with documented hypersensitivity to any of the components of the therapy programXx_NEWLINE_xXPatients will not be eligible if they have a history of hypersensitivity to tranexamic acidXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulationXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXPatients with known prior hypersensitivity reaction to any of the study drugsXx_NEWLINE_xXHypersensitivity to durvalumab or tremelimumab, or any excipients on the formulationXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to tremelimumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to the combination or comparator agentXx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXDocumented hypersensitivity to bumetanide or sulfonamidesXx_NEWLINE_xXHas hypersensitivity to nivolumab or any other drug used in this protocolXx_NEWLINE_xXPrior hypersensitivity to monoclonal antibodiesXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compoundsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition.Xx_NEWLINE_xXKnown or suspected intolerance or hypersensitivity to IT-141 or any of the stated ingredients.Xx_NEWLINE_xXPatients who have a history of ataxia telangiectasia or other documented history of radiation hypersensitivityXx_NEWLINE_xXPatients with known hypersensitivity to 5-azacitdine or MK3475 or any of their excipientsXx_NEWLINE_xXKnown hypersensitivity to any component of the investigational productsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity or intolerance to metforminXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown hypersensitivity to any of the excipients of ribociclib or bicalutamide.Xx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXHistory of hypersensitivity to durvalumab, tremelimumab, SGI-110, or any excipientXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to taxanes and drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHistory of hypersensitivity to pembrolizumab, docetaxel, gemcitabine, pemetrexed or any of their excipientsXx_NEWLINE_xXKnown hypersensitivity to study drugs;Xx_NEWLINE_xXKnown prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to one or more of the study agentsXx_NEWLINE_xXSubject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived productsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXOnly for subjects enrolled in Arm 1 - Neratinib and everolimus: history of hypersensitivity to everolimus.Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody or study drug componentsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumabXx_NEWLINE_xXKnown hypersensitivity to any of the excipients of ribociclib (LEE-011)Xx_NEWLINE_xXKnown prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXSubjects with known hypersensitivity to study drugs or their excipientsXx_NEWLINE_xXKnown hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXHypersensitivity to pembrolizumab or lanreotide or any of their excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoidXx_NEWLINE_xXKnown hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXKnown hypersensitivity to pomalidomide, dexamethasone, or any excipients in elotuzumab, formulation, or recombinant proteinXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies or carboplatin >= grade 3, any history of anaphylaxis, or uncontrolled asthmaXx_NEWLINE_xXHistory of hypersensitivity to durvalumab, tremelimumab, or any excipient.Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXKnown hypersensitivity to an component of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to anetumab ravtansine, study drug classes or excipients in the formulationXx_NEWLINE_xXKnown hypersensitivity or intolerance to any of the agents under investigationXx_NEWLINE_xXHypersensitivity to any of the investigational agents under test, or any excipient of these productsXx_NEWLINE_xXPatients with a known hypersensitivity to any of the investigational agents or any of the excipients of the productsXx_NEWLINE_xXPrevious severe hypersensitivity reaction to another monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to any of the study agents usedXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.Xx_NEWLINE_xXHave known hypersensitivity to the active substance or to an excipient of the study treatments.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to study drug and/or drug classXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinXx_NEWLINE_xXKnown hypersensitivity to any component of the nivolumab or ipilimumab productXx_NEWLINE_xXDocumented allergic or acute hypersensitivity reaction attributed to antibody treatmentsXx_NEWLINE_xXHas a known hypersensitivity to any of the study therapy productsXx_NEWLINE_xXAllergic reactions or acute hypersensitivity reaction attributed to antibody treatmentsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to paclitaxel or any of its excipients.Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of ribociclib, aromatase inhibitors (such as letrozole) or fulvestrantXx_NEWLINE_xXHistory of hypersensitivity to durvalumab (MEDI4736), tremelimumab, or any excipientXx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXHistory of hypersensitivity to TAK-228 or metforminXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived productsXx_NEWLINE_xXKnown hypersensitivity to any study drug used in this trialXx_NEWLINE_xXHypersensitivity to ruxolitinib or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXAllergic reaction/hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumabXx_NEWLINE_xXKnown hypersensitivity to any of the excipients of ribociclib or doxorubicinXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown severe (grade >= 3 NCI-CTCAE version [v]4.03) hypersensitivity reactions to monoclonal antibodies, including hypersensitivity to the investigational agent or any component in its formulations, or history of anaphylaxisXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or analogsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustineXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to afatinib or its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor®, or history of hypersensitivity type reaction to polysorbate 80 or other components of the formulation of OraxolXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to immunoglobulins or any other component of the study drugXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown or presumed hypersensitivity to decitabine or pembrolizumab (or any of their excipients)Xx_NEWLINE_xXPatient has known hypersensitivity to the components of the study drugs or any analogsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab, tremelimumab, olaparib or, any excipientXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal AntibodiesXx_NEWLINE_xXHypersensitivity to pembrolizumab or ibrutinib or any of their excipientsXx_NEWLINE_xXPatient has known hypersensitivity to the components of the study drugs or their analogsXx_NEWLINE_xXKnown hypersensitivity to deferasiroxXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown hypersensitivity to any component of the investigational productXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2879552 or lysine-specific demethylase 1 (LSD1) inhibitors that contraindicates their participationXx_NEWLINE_xXKnown hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXKnown hypersensitivity to any study drugXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to AZD1775, irinotecan, or any excipients of these agentsXx_NEWLINE_xXKnown hypersensitivity to nintedanib, gemcitabine and nab-Paclitaxel, peanut or soy or any other trial drug, their excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to cyclophosphamide, fludarabine or IL-2.Xx_NEWLINE_xXKnown hypersensitivity to either study drug (umbralisib or ibrutinib)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine or aldesleukinXx_NEWLINE_xXKnown hypersensitivity to S-1 or its metabolites (eg, 5-FU);Xx_NEWLINE_xXHypersensitivity to bevacizumab, cyclophosphamide, pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPrior hypersensitivity to bevacizumab or toxicity requiring discontinuation of bevacizumabXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabineXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXKnown hypersensitivity to GT0918 or its excipients.Xx_NEWLINE_xXKnown hypersensitivity to any excipient contained in the brentuximab formulationXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to the study drugs or the drugs with similar chemical structuresXx_NEWLINE_xXHypersensitivity to pembrolizumab, azacitidine, mannitol, or any of their excipientsXx_NEWLINE_xXHistory of grade 3 or above hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXKnown hypersensitivity to any of the components of LMB-100Xx_NEWLINE_xXParticipants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxelXx_NEWLINE_xXHistory of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug (e.g., hypersensitivity or allergy to murine products).Xx_NEWLINE_xXPatients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins are not eligibleXx_NEWLINE_xXKnown hypersensitivity to any of the components of LMB-100Xx_NEWLINE_xXParticipants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxelXx_NEWLINE_xXKnown hypersensitivity to one or more of the study agentsXx_NEWLINE_xXPatients with a history of hypersensitivity to bosutinib or axitinibXx_NEWLINE_xXHistory of any serious adverse reaction or hypersensitivity to cytarabine, unless reaction is deemed irrelevant to the study by the Investigator and Medical MonitorXx_NEWLINE_xXPatients with history of hypersensitivity to monoclonal antibodiesXx_NEWLINE_xXHistory of hypersensitivity to any of the kinase inhibitors included in this studyXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agentXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this studyXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Hypersensitivity to study therapies and its excipientsXx_NEWLINE_xXHas a known hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXSubject has a known allergic/hypersensitivity to investigational components or excipients (doxorubicin, trehalose, monoclonal antibody therapy, penicillin class of antibiotics, gentamicin (or other aminoglycosides), or ciprofloxacin hydrochloride (or other quinolones)).Xx_NEWLINE_xXHistory of hypersensitivity to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any excipients of these agentsXx_NEWLINE_xXKnown hypersensitivity to the trial drugs (volasertib and romidepsin)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown or possible hypersensitivity to palbociclib, fulvestrant, goserelin (if applicable) or to any of their excipientsXx_NEWLINE_xXPrior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine, or study drugs involved in this protocol, or to a monoclonal antibody or prior hypersensitivity to platinum-containing agentsXx_NEWLINE_xXKnown hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to paclitaxel or carboplatin or their excipientsXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to the combination or comparator agentXx_NEWLINE_xXKnown hypersensitivity to letrozole or fulvestrant, or any of its excipients, or to any palbociclib excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients with known history of hypersensitivity to paclitaxel that did not resolve with pre-medicationXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to any component of ado-trastuzumab emtansineXx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil, capecitabine, bevacizumab or to any component of the investigational products or compounds of similar chemical compositionXx_NEWLINE_xXKnown hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic compositionXx_NEWLINE_xXKnown hypersensitivity to exemestane or its excipientsXx_NEWLINE_xXKnown hypersensitivity to nintedanib, any other trial drug, or their excipientsXx_NEWLINE_xXHistory of hypersensitivity to hydrogel.Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXA known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, HH1 or Betalutin.Xx_NEWLINE_xXKnown hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant proteinXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this studyXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to any study drug component.Xx_NEWLINE_xXHypersensitivity to pembrolizumab, vorinostat or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulationXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other mAbsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatient has known hypersensitivity to any of the excipients of ribociclibXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of hypersensitivity to MEDI4736 or any excipientXx_NEWLINE_xXHistory of hypersensitivity to tremelimumab or the combination of MEDI4736 + tremelimumabXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipients.Xx_NEWLINE_xXHypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to other monoclonal antibodiesXx_NEWLINE_xXSubjects with a known hypersensitivity to fulvestrant or any of its formulation components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate.Xx_NEWLINE_xXKnown hypersensitivity reactions to any of the components of Sym004Xx_NEWLINE_xXHistory of hypersensitivity to durvalumab or tremelimumab or any excipientXx_NEWLINE_xXHypersensitivity to simvastatin or ezetimibe.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of atezolizumab or nab-paclitaxelXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatients with known hypersensitivity to taxanes or platinums are to be excludedXx_NEWLINE_xXDocumented allergy or hypersensitivity to monoclonal antibodies (bevacizumab), to Chinese hamster ovarian cells of the or to any other humanized or recombinant antibodiesXx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXKnown or possible hypersensitivity to palbociclib (CTCAE version [V] 4.03)Xx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies (Grade ?3), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partially controlled asthma Global Initiative for Asthma 2011)Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXPatients with known hypersensitivity to the components of the study drugs or their analogsXx_NEWLINE_xXA history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)Xx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or tremelimumabXx_NEWLINE_xXKnown sensitivity to kanamycin and other aminoglycosides; patients with known hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excludedXx_NEWLINE_xXNo history of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXNo known hypersensitivity to rat monoclonal antibodiesXx_NEWLINE_xXKnown intolerance or hypersensitivity to rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: History of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXAT THE TIME OF INFUSION: History of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXHas known hypersensitivity to MK-3475 (pembrolizumab) or any of its incipientsXx_NEWLINE_xXPatients with a known hypersensitivity to gemcitabine (Arm B only)Xx_NEWLINE_xXSubject has a known hypersensitivity to pembrolizumab or any of its ingredientsXx_NEWLINE_xXKnown hypersensitivity to any component of the product (lenvatinib or ingredients).Xx_NEWLINE_xXKnown hypersensitivity to any of the components of talazoparibXx_NEWLINE_xXNo history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXHistory of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPrior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5–fluorouracilXx_NEWLINE_xXHistory of hypersensitivity to any component of the formulationXx_NEWLINE_xXKnown hypersensitivity to afatinib or the excipients of any of the trial drugsXx_NEWLINE_xXHas known hypersensitivity to pembrolizumab (MK-3475) or its formulationXx_NEWLINE_xXKnown hypersensitivity to S-equol or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to any of the products used in the trial – G-CSF (Neupogen, filgrastim), plerixafor (Mozobil), or any components of the chemotherapeutic agents or O6BG/BCNU in vivo selection regimensXx_NEWLINE_xXPatients with a known hypersensitivity to interferon-alphaXx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHistory of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCL) or the components of doxil, paclitaxel, or carboplatinXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxideXx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXHistory of hypersensitivity to MEDI4736 or any excipient.Xx_NEWLINE_xXHistory of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulationsXx_NEWLINE_xXKnown hypersensitivity to 5-FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, Bravavir, etc.)Xx_NEWLINE_xXHistory of hypersensitivity to active or inactive excipients of any component of treatmentXx_NEWLINE_xXKnown hypersensitivity or infusion reaction to cisplatin and gemcitabineXx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXHistory of hypersensitivity to paclitaxelXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO) or to thyrotropin alpha (Thyrogen)Xx_NEWLINE_xXPrior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXSevere hypersensitivity reaction to treatment with another monoclonal antibodyXx_NEWLINE_xXPatients with documented hypersensitivity to any components of the study programXx_NEWLINE_xXSubjects with history of hypersensitivity to azolesXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXPatient with documented hypersensitivity to any of the components of the chemotherapy programXx_NEWLINE_xXPatients with a known hypersensitivity to BKM120 or to its excipientsXx_NEWLINE_xXPatient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) or interferon-alpha2b (IFN-a2b)Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO), or to compounds of similar chemical or biologic composition to navitoclaxXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of PFK-158.Xx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXKnown hypersensitivity to any of the components of MM-398 or other liposomal productsXx_NEWLINE_xXHistory of hypersensitivity to mannitolXx_NEWLINE_xXHistory of allergic reactions or hypersensitivity to the study drugs (hydroxychloroquine, gemcitabine, Abraxane)Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXNo known hypersensitivity to murine productsXx_NEWLINE_xXPatients with known hypersensitivity to pegfilgrastim and filgrastimXx_NEWLINE_xXKnown contraindication or hypersensitivity to any component of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to any component of AvastinXx_NEWLINE_xXPatient has a known hypersensitivity or contraindication to study products that, in the opinion of the investigator, cannot be adequately pre-medicatedXx_NEWLINE_xXKnown hypersensitivity to one or more of the study agentsXx_NEWLINE_xXKnown hypersensitivity to bevacizumab or any of its excipients or any other study drugXx_NEWLINE_xXPatients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compoundsXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXHypersensitivity of TZDXx_NEWLINE_xXKnown hypersensitivity or other serious adverse reaction to any azole antifungal therapy or to any other ingredient of the study medication used.Xx_NEWLINE_xXSubjects must not have a known history of hypersensitivity to mannitolXx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXSevere or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody therapyXx_NEWLINE_xXKnown or suspected hypersensitivity to ruxolitinib.Xx_NEWLINE_xXMust not have a known or suspected hypersensitivity to azacitidine, mannitol, or compounds of similar composition to azacitidineXx_NEWLINE_xXPatients with known hypersensitivity to any excipient contained in the drug formulation.Xx_NEWLINE_xXSevere allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational productXx_NEWLINE_xXKnown hypersensitivity to 5AC or GM-CSFXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this studyXx_NEWLINE_xXPatient has known hypersensitivity to the components of study drug or its analogsXx_NEWLINE_xXPrior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101Xx_NEWLINE_xXPatient with documented hypersensitivity to any of the component medicationsXx_NEWLINE_xXHypersensitivity to mithramycinXx_NEWLINE_xXHistory of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulationXx_NEWLINE_xXHistory of hypersensitivity to sirolimus, temsirolimus, everolimusXx_NEWLINE_xXHistory of hypersensitivity to any component of the formulationXx_NEWLINE_xXPatients with known hypersensitivity to the components of study drug or its analogsXx_NEWLINE_xXHistory of hypersensitivity to bevacizumab, murine products, or any component of the formulationXx_NEWLINE_xXHistory of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulationXx_NEWLINE_xXHistory of hypersensitivity to cetuximab, murine products, or any component of the formulationXx_NEWLINE_xXHistory of hypersensitivity to vemurafenibXx_NEWLINE_xXHistory of hypersensitivity to sorafenib for vemurafenib/sorafenib armXx_NEWLINE_xXHistory of hypersensitivity to crizotinib for vemurafenib/crizotinib armXx_NEWLINE_xXHistory of hypersensitivity to any component of the formulationXx_NEWLINE_xXHistory of hypersensitivity to temsirolimus or metforminXx_NEWLINE_xXPatient with documented hypersensitivity to any of the components of the chemotherapy programXx_NEWLINE_xXNo prior known allergic reaction to monoclonal antibodiesXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukinXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to abiraterone acetate, apalutamide or prednisone or their excipientsXx_NEWLINE_xXPatients with history of hypersensitivity to conductive hydrogel are not eligibleXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of hypersensitivity active or inactive excipients of AZD9291 (osimertinib) or drugs with a similar chemical structure or class to AZD9291 (osimertinib)Xx_NEWLINE_xXHypersensitivity to decitabine, guadecitabine, or any of their excipients.Xx_NEWLINE_xXKnown hypersensitivity to enzalutamide or any of its components.Xx_NEWLINE_xXPatients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.Xx_NEWLINE_xXHistory of severe hypersensitivity reactions to other mAbsXx_NEWLINE_xXPatients in Part E or Part F: history of severe immune-mediated adverse reactions or severe hypersensitivity to pembrolizumabXx_NEWLINE_xXKnown hypersensitivity to any component of axitinib or prior use of axitinibXx_NEWLINE_xXPatients who are (MVF-HER-2[266-296] and MVF-HER-2 [597-626]) immediate hypersensitivity skin test positiveXx_NEWLINE_xXPatients with a known hypersensitivity to any of the study agentsXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXPrior history of hypersensitivity reactions to oxaliplatin, bevacizumab, fluorouracil (5-FU) or capecitabineXx_NEWLINE_xXKnown severe hypersensitivity to trastuzumab (excluding mild to moderate infusion reactions that are easily managed and do not recur)Xx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXKnown hypersensitivity to any component of topotecan or doxorubicin or other required drugs in the studyXx_NEWLINE_xXKnown hypersensitivity to thalidomide.Xx_NEWLINE_xXKnown hypersensitivity to any component of the study medication(s).Xx_NEWLINE_xXSubject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to the IP or its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity to monoclonal antibodies (mAbs).Xx_NEWLINE_xXHas hypersensitivity to eribulin or any of the excipientsXx_NEWLINE_xXAllergies, hypersensitivity, or intolerance to niraparib or the corresponding excipientsXx_NEWLINE_xXPatient with known hypersensitivity to receptor tyrosine kinase inhibitors or any of the components of poziotinib tablets or T-DM1 IV solution.Xx_NEWLINE_xXKnown hypersensitivity to ASN007 or its excipients;Xx_NEWLINE_xXHypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody productsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies.Xx_NEWLINE_xXHistory of prior ? grade 3 hypersensitivity reaction or any toxicity attributed to trastuzumab or murine proteins that warranted permanent cessation of these agents (applicable for Cohort 1 only).Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXSubjects who have a hypersensitivity to aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXPatients who have received prior treatment with a PI3K inhibitor or have known hypersensitivity to Gedatolisib or its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipient.Xx_NEWLINE_xXhypersensitivity to the active substance or to any of the excipients of study drug;Xx_NEWLINE_xXPatients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;Xx_NEWLINE_xXKnown hypersensitivity to any of the excipients of INC280Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).Xx_NEWLINE_xXHypersensitivity to the active pharmaceutical ingredient or any of the excipients of the IMPs, including Labrasol, butylated hydroxyanisole, and butylated HydroxytolueneXx_NEWLINE_xXPrior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHave a history of hypersensitivity reaction to any of the components of TemozolomideXx_NEWLINE_xXHave a history of hypersensitivity to dacarbazine (DTIC)Xx_NEWLINE_xXAllergies or hypersensitivity to murine, chimeric, human or humanised proteinsXx_NEWLINE_xXHas known hypersensitivity to TAS-119 or its components.Xx_NEWLINE_xXHas known hypersensitivity to Cremophor® EL, paclitaxel or its components.Xx_NEWLINE_xXHistory or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;Xx_NEWLINE_xXPatients with a known hypersensitivity to BKM120 or to its excipientsXx_NEWLINE_xXPatient with hypersensitivity to bortezomib, boron or dexamethasoneXx_NEWLINE_xXHistory of hypersensitivity to a taxaneXx_NEWLINE_xXHypersensitivity to fluphenazine or other phenothiazinesXx_NEWLINE_xXKnown hypersensitivity to recombinant proteins or any excipient contained in the drug formulationXx_NEWLINE_xXHypersensitivity to AQ4N or to any ingredients contained in the drug formulation.Xx_NEWLINE_xXHypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine (DTIC).Xx_NEWLINE_xXSubjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.Xx_NEWLINE_xXKnown hypersensitivity to MMB, its metabolites, or formulation excipientsXx_NEWLINE_xXSteroids as premedication for hypersensitivity reactions are permitted;Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2857916, or any of the components of the study treatment.Xx_NEWLINE_xXKnown prior severe hypersensitivity to investigational products or any component in their formulationsXx_NEWLINE_xXHistory of allergy or hypersensitivity to gemcitabine (or other drug excipients in TAR-200) or drugs chemically-related to gemcitabine.Xx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXPatients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXParticipant has hypersensitivity to any component of TMZ or dacarbazine.Xx_NEWLINE_xXAny known hypersensitivity or contraindication to the components of the study drug AZD1775Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant antibodiesXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the product.Xx_NEWLINE_xXHypersensitivity to any reagents used in the study.Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to GSK2857916, or any of the components of the study treatment.Xx_NEWLINE_xXKnown hypersensitivity to any study drugXx_NEWLINE_xXHas severe hypersensitivity (?Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or any of its excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXPatients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the productXx_NEWLINE_xXSevere hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomabXx_NEWLINE_xXKnown hypersensitivity to any of the components of talazoparibXx_NEWLINE_xXKnown hypersensitivity to any temozolomide component or to dacarbazine (DTIC).Xx_NEWLINE_xXKnown hypersensitivity to irinotecan or its excipients.Xx_NEWLINE_xXHistory of hypersensitivity to cyclophosphamide, fludarabine or IL-2Xx_NEWLINE_xXSubject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipientsXx_NEWLINE_xXKnown hypersensitivity to enzalutamideXx_NEWLINE_xXPatients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study materialXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXAny known hypersensitivity or contraindication to the components of the study drug AZD1775 or olaparib.Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.Xx_NEWLINE_xXKnown or possible hypersensitivity to fulvestrant, or palbociclib or any of their excipients.Xx_NEWLINE_xXPre/perimenopausal women with a known hypersensitivity to gonadotrophin releasing hormone (gnRH).Xx_NEWLINE_xXPatients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligibleXx_NEWLINE_xXHistory of severe hypersensitivity reaction with biologics therapy (monoclonal antibodies)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of any hypersensitivity or allergic reaction to any beta lactam antibiotic, tazobactam, or any study therapy (IV or oral)Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to the components of study drugs or analogs of study drugsXx_NEWLINE_xXPatient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or epacadostat or any of their excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to any of the study agentsXx_NEWLINE_xXHypersensitivity to pembrolizumab, epacadostat or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown hypersensitivity to monoclonal antibodiesXx_NEWLINE_xXKnown hypersensitivity to fluorouracil (5-FU), oxaliplatin, or other platinum agentsXx_NEWLINE_xXKnown hypersensitivity to nab-paclitaxel or any of its excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the product.Xx_NEWLINE_xXHistory of hypersensitivity to durvalumab, guadecitabine (SGI-110) or any excipientXx_NEWLINE_xXSubject has known allergies, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived productsXx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHypersensitivity to acetazolamide or sulfonamidesXx_NEWLINE_xXPatient with documented hypersensitivity to any of the components of the chemotherapy programXx_NEWLINE_xXHas prior allergic reaction or hypersensitivity to celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity or intolerance to any of the agents under investigationXx_NEWLINE_xXKnown hypersensitivity to any of the components of PRI?724, fluorouracil (5?FU), oxaliplatin or bevacizumabXx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of BYL719 (alpelisib)Xx_NEWLINE_xXKnown hypersensitivity to arsenic trioxideXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to the combination or comparator agent (If applicable)Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatients with a history of severe (grade >= 3) hypersensitivity reaction to a monoclonal antibody are ineligibleXx_NEWLINE_xXKnown hypersensitivity to any components of study drugsXx_NEWLINE_xXHave a known hypersensitivity to any of the components of AG-120, matched placebo, or azacitidine.Xx_NEWLINE_xXAny serious known immediate or delayed hypersensitivity reaction to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drugs. Additionally, any known hypersensitivity to either enzalutamide, abiraterone or any excipients would be excluded.Xx_NEWLINE_xXKnown hypersensitivity to Cremophor®-based agentsXx_NEWLINE_xXpatient has known hypersensitivity to alpelisib, fulvestrant or letrozoleXx_NEWLINE_xXKnown hypersensitivity reaction to GM-CSFXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may pose an increased risk of a serious infusion reaction.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHave known hypersensitivity to the active substance or to an excipient for a study treatment.Xx_NEWLINE_xXHypersensitivity to decitabine, guadecitabine, or any of their excipients.Xx_NEWLINE_xXA known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or any of their excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug or vehicle formulation for margetuximab or pembrolizumab.Xx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or guadecitabine formulationsXx_NEWLINE_xXHistory of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXNo known hypersensitivity to Escherichia (E.) coli-derived productsXx_NEWLINE_xXPatients with a prior hypersensitivity reaction to sargramostimXx_NEWLINE_xXPrior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of study drug excipientsXx_NEWLINE_xXThe subject has a history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC)Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe allergic, anaphylactic or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or any of the study drugsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec (T-VEC) or any of its componentsXx_NEWLINE_xXHypersensitivity to MK-3475 (pembrolizumab) or any of its excipients;Xx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXPatients with a known hypersensitivity to gemtuzumab ozogamicin or its parts: recombinant humanized anti-CD33 monoclonal (hP67.6) antibody, calicheamicin derivatives or other ingredientsXx_NEWLINE_xXTREATMENT: Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib dimethyl sulfoxide (DMSO), its excipients, or DMSO, are ineligible to receive treatment with trametinib DMSOXx_NEWLINE_xXTREATMENT: Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib DMSO, its excipients, or DMSO, are ineligible to receive treatment with trametinib DMSOXx_NEWLINE_xXTREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomideXx_NEWLINE_xXKnown hypersensitivity to any of the components of tazemetostatXx_NEWLINE_xXKnown prior or suspected hypersensitivity to study drugs or any component in their formulationsXx_NEWLINE_xXAny history of a severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to pembrolizumab, binimetinib, or any excipients of either drugXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHypersensitivity to mithramycinXx_NEWLINE_xXKnown hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulationXx_NEWLINE_xXPatients who have severe hypersensitivity to irinotecan hydrochloride (HCl)Xx_NEWLINE_xXKnown hypersensitivity to cetuximab or other EGFR antibodyXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to any of the products used in the trial-G-CSF (Neupogen), plerixafor, or any planned components of conditioning regimensXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown hypersensitivity to inactive ingredient of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to inactive ingredient of TPI 287Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL-2 or any component of the formulationXx_NEWLINE_xXHistory of allergic or idiosyncratic/hypersensitivity reactions to 8-methoxypsoralen/psoralen compoundsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipientsXx_NEWLINE_xXKnown documented or suspected hypersensitivity to the components of the study drug(s) or analogsXx_NEWLINE_xXPrior known allergic reaction to pembrolizumab or its excipientsXx_NEWLINE_xXPatients must not have a history of hypersensitivity to active or inactive excipients of AZD4547 or drugs with a similar chemical structure or class to AZD4547Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXSubjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other antigenXx_NEWLINE_xXKnown hypersensitivity to ledipasvir, sofosbuvir, or formulation excipientsXx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of buparlisibXx_NEWLINE_xXPatient has a known hypersensitivity to ribociclib or excipients of tamoxifenXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatient has known hypersensitivity to any of the excipients of ribociclibXx_NEWLINE_xXKnown hypersensitivity to any of the study agents usedXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to AT13387Xx_NEWLINE_xXSubject has a known hypersensitivity to any of the excipients of nab-paclitaxel or BYL719/alpelisibXx_NEWLINE_xXHistory of hypersensitivity to dacarbazineXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agentXx_NEWLINE_xXHypersensitivity to trial medications (everolimus)Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to any of the following: bortezomib, boron, mannitolXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXPatients with hypersensitivity to excipients of the study drug are not eligibleXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHypersensitivity to any of the study medicationsXx_NEWLINE_xXPatients with known hypersensitivity to temozolomide or dacarbazine are not eligibleXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXSerious hypersensitivity reaction to egg productsXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcoholXx_NEWLINE_xXKnown hypersensitivity to afatinib, dasatinib, or the excipients of any of the trial drugsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO) or GSK214795Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXPatients with known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the trametinib, GSK2141795 or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXWith known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate)Xx_NEWLINE_xXNo history of hypersensitivity to murine protein containing productsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the product; patients with known hypersensitivity cetuximab or any of the excipients of the productXx_NEWLINE_xXA history of ataxia telangiectasia or other documented history of radiation hypersensitivityXx_NEWLINE_xXPatients who have hypersensitivity to sitagliptinXx_NEWLINE_xXPatients will be excluded if there is any history of allergic reaction(s) attributed to compounds of similar composition to temsirolimus, sorafenib, their metabolites, or any component of their formulation (including excipients and polysorbate 80); this includes hypersensitivity to macrolide antibiotics due to potential for cross-reactivity with temsirolimusXx_NEWLINE_xXPatients with previous hypersensitivity reaction to camptothecins are excludedXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of oxaliplatin or mitomycin CXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of oxaliplatin or mitomycin CXx_NEWLINE_xXDocumented hypersensitivity to clobetasolXx_NEWLINE_xXPatients with a known hypersensitivity to RAD001(everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXMust not have known hypersensitivity to 4-aminoquinoline compoundXx_NEWLINE_xXPatients with a known hypersensitivity to BKM120, RAD001 (including other rapalogs) or their excipientXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXPatients with known hypersensitivity to anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearateXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXSystemic hypersensitivity to Montanide ISA 51 VG or any vaccine componentXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXSystemic hypersensitivity to Montanide ISA 51 VG or any vaccine componentXx_NEWLINE_xXPrevious history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogsXx_NEWLINE_xXPatient has hypersensitivity to VELCADE (bortezomib), boron, or mannitolXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodiesXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)Xx_NEWLINE_xXPatients with a history of a hypersensitivity reaction to products containing polysorbate 80 (Tween 80)Xx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXHypersensitivity to interferon-alpha (IFN-alpha)Xx_NEWLINE_xXHypersensitivity to interferon alfaXx_NEWLINE_xXSuspected hypersensitivity to IFN alfa2bXx_NEWLINE_xXThis criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodiesXx_NEWLINE_xXParticipants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).Xx_NEWLINE_xXHas a known severe hypersensitivity (> Grade 3) to pembrolizumab, its active substance and/or any of its excipients.Xx_NEWLINE_xXSubject with known or suspected hypersensitivity to seviteronel, or any components of the formulationXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies.Xx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.Xx_NEWLINE_xXContraindications or history of allergic reaction to lapatinib or to capecitabine, known dihydropyrimidine dehydrogenase deficiency, or known hypersensitivity of 5-fluorouracilXx_NEWLINE_xXPatients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).Xx_NEWLINE_xXPatients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of talazoparibXx_NEWLINE_xXParticipant who has hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXHistory of severe hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigatorXx_NEWLINE_xXHas a history of severe hypersensitivity reaction (e.g. generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to pembrolizumab, gemcitabine, carboplatin, or cisplatin or their analogs and/or to any of their excipients.Xx_NEWLINE_xXPatients with a history of hypersensitivity to sirolimus or any component of the formulation.Xx_NEWLINE_xXhypersensitivity to trastuzumab, murine proteins, fulvestrant, or to any of the excipientsXx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)Xx_NEWLINE_xXHistory of intolerance or hypersensitivity to study drugXx_NEWLINE_xXHistory of prior grade 3 or 4 hypersensitivity or any toxicity to trastuzumab that warranted permanent cessation of this antibodyXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.Xx_NEWLINE_xXHypersensitivity to erlotinib or alectinib or to any of the excipients.Xx_NEWLINE_xXSubject has a history of hypersensitivity to porcine derived gelatin or collagen.Xx_NEWLINE_xXSubject has a history of hypersensitivity to microbial Transglutaminase.Xx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patients must not have an immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients, or to dimethyl sulfoxide (DMSO) or other agents used in the studyXx_NEWLINE_xXKnown history of immunogenicity or hypersensitivity to a CD25 antibody.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of RO6958688 and/or obinutuzumabXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus that in the opinion of the investigator contraindicates their participationXx_NEWLINE_xXHypersensitivity to ASTX660, excipients of the drug product, or other components of the study treatment regimen.Xx_NEWLINE_xXKnown hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trialXx_NEWLINE_xXSubject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsinXx_NEWLINE_xXKnown hypersensitivity to any study drug componentXx_NEWLINE_xXHistory of allergic reactions to carboplatin, platinum containing compounds or mannitol and/or hypersensitivity to PLD or to any of the excipientsXx_NEWLINE_xXFor Combination Dose Finding and Combination Expansion cohorts only: history of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the lead principal investigator (PI)Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients, or to dimethyl sulfoxide (DMSO), or to Cremophor EL (polyoxyethylated castor oil); please note, exclusion for Cremophor is unnecessary unless paclitaxel is the only agent available and the patient randomizes to the conventional therapy optionXx_NEWLINE_xXKnown hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.Xx_NEWLINE_xXKnown hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2Xx_NEWLINE_xXKnown severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib/placebo excipients or to endocrine treatments.Xx_NEWLINE_xXKnown hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.Xx_NEWLINE_xXPatients must not have any known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXKnown hypersensitivity to any excipients of tesevatinib.Xx_NEWLINE_xXKnown or suspected hypersensitivity to the excipients contained in the formulation of durvalumab, lenalidomide, or dexamethasoneXx_NEWLINE_xXKnown intolerance to the study drug or any of the excipients.Xx_NEWLINE_xXKnown allergic reaction to any component of MEDI1873Xx_NEWLINE_xXPreviously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).Xx_NEWLINE_xXKnown hypersensitivity to any of the GTx-024 components or subjects previously received treatment with SARMXx_NEWLINE_xXKnown intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate 80.Xx_NEWLINE_xXParticipants who had a prior exposure to trabectedin or hypersensitivity to any of the excipients will not be excluded from receiving single-agent DoxilXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipientsXx_NEWLINE_xXHave a history of hypersensitivity to human or mouse antibody products.Xx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXHas known hypersensitivity to any of the components of IP.Xx_NEWLINE_xXHave a known hypersensitivity to investigator's choice of standard of care (gemcitabine or capecitabine).Xx_NEWLINE_xXPatients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorinXx_NEWLINE_xXHas a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to axitinib or sunitinib.Xx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine, mannitol, or durvalumab, its constituents, or to any other humanized monoclonal antibody.Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of ribociclibXx_NEWLINE_xXKnown hypersensitivity reaction to the GM-CSF adjuvant; Any known contra-indication to GM-CSF or Cyclophosphamide treatment;Xx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXHypersensitivity or prior treatment with obinutuzumabXx_NEWLINE_xXKnown hypersensitivity to the study treatment or any of its ingredients.Xx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies (Grade greater than or equal to (>=) 3 NCI CTCAE v 4.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)Xx_NEWLINE_xXPrevious severe hypersensitivity reaction to another Monoclonal antibody. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the excipients in pazopanib tabletsXx_NEWLINE_xXPatients must not have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation or known hypersensitivity to any component of cobimetinib or vemurafenibXx_NEWLINE_xXGSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drug.Xx_NEWLINE_xXKnown hypersensitivity to pharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXNo prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDsXx_NEWLINE_xXSubject has known hypersensitivity to immunoglobulins or any of the products or components to be administered during dosing.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulationXx_NEWLINE_xXHave a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.Xx_NEWLINE_xXKnown history of immunogenicity or hypersensitivity to a CD19 antibody.Xx_NEWLINE_xXKnown hypersensitivity to study drug, study drug classes or excipients of the formulation.Xx_NEWLINE_xXNo known hypersensitivity to gemcitabine or nab-paclitaxelXx_NEWLINE_xXIntolerance or hypersensitivity to octreotideXx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil/leucovorinXx_NEWLINE_xXKnown hypersensitivity to irinotecanXx_NEWLINE_xXKnown hypersensitivity to any of the components of MM-398, other liposomal products, fluoropyrimidines or leucovorinXx_NEWLINE_xXHave known or suspected hypersensitivity to azacitidine or any other ingredient used in the manufacturing of Azacitidine.Xx_NEWLINE_xXKnown hypersensitivity to the components of the study therapy or its analogs.Xx_NEWLINE_xXKnown hypersensitivity to the components of the study therapy. (Please reference Section 1, Formulation of EC1169 and EC0652, in the respective Pharmacy Manuals)Xx_NEWLINE_xXKnown hypersensitivity to momelotinib, its metabolites, or formulation excipientsXx_NEWLINE_xXSevere hypersensitivity reaction to treatment with another monoclonal antibody (mAb)Xx_NEWLINE_xXHypersensitivity to the active ingredient or any of the excipients including lactose.Xx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or rituximabXx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXHistory of severe hypersensitivity reaction to study treatments or their excipients.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cellsXx_NEWLINE_xXKnown hypersensitivity to any of plitidepsin's formulation componentsXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to talacotuzumab and daratumumab or their excipientsXx_NEWLINE_xXHypersensitivity to IMiDs (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the 2 first cycles or toxicity, which does meet intolerance definition.Xx_NEWLINE_xXKnown hypersensitivity to the study drugs (GS 5829, fulvestrant or exemestane), the metabolites, or formulation excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or excipientsXx_NEWLINE_xXKnown anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximabXx_NEWLINE_xXPrior treatment with or hypersensitivity to study drug or related compoundsXx_NEWLINE_xXHas a known severe hypersensitivity to pembrolizumab, its active substance and/or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to any component of lenvatinib or midazolam.Xx_NEWLINE_xXKnown hypersensitivity to mannitol.Xx_NEWLINE_xXPatient has a known hypersensitivity to Ribociclib or any of its excipients.Xx_NEWLINE_xXHistory of severe allergic or anaphylactic reaction or known sensitivity to humanized or murine monoclonal antibodiesXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab, obinutuzumab, rituximab, or bendamustine formulation, including mannitolXx_NEWLINE_xXKnown hypersensitivity to bicalutamide.Xx_NEWLINE_xXCurrent or past history of severe hypersensitivity to any other antibody productsXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to a component of protocol therapyXx_NEWLINE_xXPatients with a known hypersensitivity to any excipient contained in the drugXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other mAbs.Xx_NEWLINE_xXKnown hypersensitivity to pembrolizumab or any of its insipientsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to taxanesXx_NEWLINE_xXHistory of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.Xx_NEWLINE_xXHave known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to cytarabine, daunorubicin or liposomal productsXx_NEWLINE_xXKnown hypersensitivity to any of the components of talazoparibXx_NEWLINE_xXKnown serious reactions or hypersensitivity to any components of the UV1 vaccine or similar peptide based vaccinesXx_NEWLINE_xXKnown hypersensitivity to GM-CSFXx_NEWLINE_xXKnown hypersensitivity to any of the excipients of the investigational productsXx_NEWLINE_xXHas a known hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXPatients with known hypersensitivity to any TZD oral agents are not eligibleXx_NEWLINE_xXKnown intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXKnown hypersensitivity to the trial drugs or to their excipientsXx_NEWLINE_xXHistory of hypersensitivity to LCI699 or to drugs of similar chemical classes.Xx_NEWLINE_xXHypersensitivity to 5FU (fluorouracil), oxaliplatin (or other platinum agents), irinotecan (irinotecan hydrochloride) (or to their excipients)Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2879552 or LSD1 inhibitors that contraindicates their participation.Xx_NEWLINE_xXImmediate or delayed hypersensitivity to digoxin or trametinibXx_NEWLINE_xXPatients who have exhibited hypersensitivity reactions to regorafenib and/or a structural compound, biological agent, or formulation (e.g., sorafenib)Xx_NEWLINE_xXHistory of grade 3 or higher hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigatorXx_NEWLINE_xXKnown hypersensitivity to afatinib or letrozole or the excipients of any of the trial drugs.Xx_NEWLINE_xXSevere hypersensitivity to any pembrolizumab excipientsXx_NEWLINE_xXHistory of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulationXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this studyXx_NEWLINE_xXKnown hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycolXx_NEWLINE_xXKnown hypersensitivity to one or more of the study agentsXx_NEWLINE_xXKnown hypersensitivity to any study drugXx_NEWLINE_xXKnown hypersensitivity to any of the components of talazoparibXx_NEWLINE_xXKnown hypersensitivity to the components of niraparibXx_NEWLINE_xXPatients must not have prior significant hypersensitivity to rituximab (not including infusion reactions)Xx_NEWLINE_xXPatients with a known hypersensitivity to any excipient contained in the drug formulationXx_NEWLINE_xXPatient has hypersensitivity to VELCADE (bortezomib), boron, or mannitolXx_NEWLINE_xXHistory of hypersensitivity to anakinra.Xx_NEWLINE_xXHistory of hypersensitivity to denosumab.Xx_NEWLINE_xXHistory of hypersensitivity to everolimus.Xx_NEWLINE_xXHistory of hypersensitivity to any component of the formulation.Xx_NEWLINE_xXPatients must not have hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXSubject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS4.Xx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXPreviously known hypersensitivity to any of the agents used in this studyXx_NEWLINE_xXPatients with a known hypersensitivity to any component of bevacizumab are not eligible for this trialXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHave a history of hypersensitivity to any study drugs or their excipients, or intolerance to hydration due to preexisting pulmonary or cardiac impairment, or intolerance to opioid pain medications, or a history of severe hypersensitivity to any other antigen.Xx_NEWLINE_xXKnown prior clinically relevant hypersensitivity reaction to thalidomide, including the development of erythema nodosum if characterized by a desquamating rashXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or any component of the atezolizumab formulationXx_NEWLINE_xXSevere hypersensitivity reaction to treatment with another monoclonal antibodyXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of an investigational treatment will be excluded from participation in the corresponding arm but are eligible for participation in other study arm; Patients that have a history of hypersensitivity to rapamycin derivatives will be excluded from participation in the everolimus armXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPrior severe hypersensitivity reaction to another monoclonal antibody (mAb)Xx_NEWLINE_xXSteroids for the treatment of hypersensitivity or transfusion reactions, nausea/vomiting or painXx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of ribociclib or letrozoleXx_NEWLINE_xXPatients with known hypersensitivity to any oligodeoxynucleotide.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXParticipant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodiesXx_NEWLINE_xXKnown hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or pembrolizumab.Xx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXKnown intolerance or hypersensitivity to progesterone or its excipientsXx_NEWLINE_xXHistory of hypersensitivity to castor oilXx_NEWLINE_xXPatients with a history of severe hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80Xx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiencyXx_NEWLINE_xXKnown hypersensitivity to capecitabine, fluorouracil, or any component of the formulationXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXPatients with a known hypersensitivity to ribociclib or everolimus or to its excipients.Xx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to any form of heparin or azacitidineXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXImmediate or delayed hypersensitivity to digoxinXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXKnown hypersensitivity to pembrolizumab or any of its excipients and/or liposomal doxorubicinXx_NEWLINE_xXPrior treatment with nintedanib (BIBF1120); known hypersensitivity to nintedanib, peanut or soya or any other trial drug, their excipients or to contrast mediaXx_NEWLINE_xXHistory of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014Xx_NEWLINE_xXPatients must not have a history of a grade 4 anaphylactic reaction to monoclonal antibody therapy or known hypersensitivity reactions to drugs formulated with polysorbate 90Xx_NEWLINE_xXHistory of hypersensitivity to ibrutinibXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to TPIV200Xx_NEWLINE_xXKnown hypersensitivity reaction to the GM-CSF adjuvantXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pegfilgrastim or Escherichia (E.) coli derived proteinsXx_NEWLINE_xXSubjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other Antigen.Xx_NEWLINE_xXAny serious known immediate or delayed hypersensitivity reaction(s) to GSK2820151 or idiosyncrasy to drugs chemically related to the investigational drug.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to ibrutinib or any component of the ibrutinib formulationXx_NEWLINE_xXNo known hypersensitivity to BIBF 1120, to its excipients or to contrast mediaXx_NEWLINE_xXParticipant has previous severe hypersensitivity reaction to another monoclonal antibody (mAb).Xx_NEWLINE_xXKnown anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximabXx_NEWLINE_xXKnown hypersensitivity to murine or chimeric antibodies or proteinsXx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity to enzalutamide or related compoundsXx_NEWLINE_xXKnown prior severe allergic/hypersensitivity to the chemotherapy or any of the components of the study treatmentXx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies (Grade ?3), any history of anaphylaxis.Xx_NEWLINE_xXPatient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)Xx_NEWLINE_xXKnown history of hypersensitivity to active or inactive excipients of HM61713 or drugs with a similar chemical structure of HM61713Xx_NEWLINE_xXContraindication to any required concomitant drugs or supportive therapies including hypersensitivity to all anticoagulation and antiplatelet options or hypersensitivity to acyclovir or similar anti-viral drugXx_NEWLINE_xXHistory of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate 80 or sodium citrate dehydrateXx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXHas known hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHas known hypersensitivity to paclitaxelXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodiesXx_NEWLINE_xXPatient has a known hypersensitivity to LEE011 or any of its excipientsXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction to carboplatin, paclitaxel, polysorbate 80, or any other component of the formulationXx_NEWLINE_xXHas known hypersensitivity to fluorouracil (5FU), oxaliplatin, or other platinum agents.Xx_NEWLINE_xXKnown hypersensitivity to pembrolizumab or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity to acyclovir or similar anti-viral drugXx_NEWLINE_xXHistory of hypersensitivity to any excipients in the investigational product.Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulationXx_NEWLINE_xXKnown hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.Xx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHas a known hypersensitivity to any of the study therapy productsXx_NEWLINE_xXKnown hypersensitivity to ibrutinibXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXNo known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.Xx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of BYL719Xx_NEWLINE_xXPatient has a known hypersensitivity to cetuximab or any other monoclonal antibodyXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agentXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to AEB071 or BYL719Xx_NEWLINE_xXPrior allergic reaction or hypersensitivity to sulfonamides (may be allowed per investigator discretion based on patient history), celecoxib or NSAIDsXx_NEWLINE_xXSubject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).Xx_NEWLINE_xXSubject has a known hypersensitivity to platinum compounds.Xx_NEWLINE_xXHistory of prior >= G 3 hypersensitivity (HSR) or any toxicity to trastuzumab or pertuzumab that warranted permanent cessation of this agentXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipientsXx_NEWLINE_xXKnown hypersensitivity to everolimus or bendamustineXx_NEWLINE_xXKnown hypersensitivity to trial drugXx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXPatients with a known hypersensitivity to BKM120 or to its excipientsXx_NEWLINE_xXA known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study drugs or their excipients that, in the opinion of the investigator or medical monitor, contraindicates participationXx_NEWLINE_xXPatients with known hypersensitivity to olaparib, AZD5363, AZD2014 or any of their excipients; patients with a history of hypersensitivity to drugs with a similar chemical structure or class to olaparib, AZD5363, or AZD2014Xx_NEWLINE_xXHistory of severe hypersensitivity reaction (>= grade 3) to polysorbate 80 containing drugsXx_NEWLINE_xXKnown anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab.Xx_NEWLINE_xXKnown hypersensitivity to any of the components of ipilimumab, bevacizumab, or nab-paclitaxelXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to vemurafenib or thyrotropin alpha (Thyrogen)Xx_NEWLINE_xXDocumented hypersensitivity to any of the drugs used in the protocolXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or excipientsXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodiesXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXSubject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).Xx_NEWLINE_xXSubject has a known hypersensitivity to platinum compounds.Xx_NEWLINE_xXKnown intolerance or hypersensitivity to vitamin E, everolimus or to rapamycin derivativesXx_NEWLINE_xXHave a known or suspected hypersensitivity to brigatinib or its excipients.Xx_NEWLINE_xXSubjects with known hypersensitivity to any of the components of AG-120.Xx_NEWLINE_xXPatients with a known hypersensitivity to BKM120 or its excipientsXx_NEWLINE_xXPatients with a history of grade >= 3 hypersensitivity reaction to trastuzumab, OR grade >= 1 with the most recent trastuzumab infusion before study entry, OR continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions are not eligible for participationXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to AA or prednisone or their excipientsXx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil/leucovorinXx_NEWLINE_xXKnown hypersensitivity to capecitabineXx_NEWLINE_xXKnown hypersensitivity to irinotecanXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to regorafenibXx_NEWLINE_xXNo history of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXKnown hypersensitivity to cytarabine, daunorubicin or liposomal productsXx_NEWLINE_xXSubjects with hypersensitivity to study drugs or their excipientsXx_NEWLINE_xXHypersensitivity to ofatumumab or its excipientsXx_NEWLINE_xXKnown hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodiesXx_NEWLINE_xXKnown hypersensitivity to any immunomodulatory drugs (IMiDs), including Grade 4 rashXx_NEWLINE_xXKnown hypersensitivity or intolerance to dexamethasoneXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cell or any component of the atezolizumab formulationXx_NEWLINE_xXHistory of hypersensitivity to active or inactive excipients of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.Xx_NEWLINE_xXHypersensitivity to any of the study medications or any of the ingredients or excipients of these medications, including hypersensitivity to benzyl alcoholXx_NEWLINE_xXKnown hypersensitivity to acyclovir or similar anti-viral drugXx_NEWLINE_xXPatients must not have known hypersensitivity reactions, such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Steven-Johnson syndrome, and toxic epidermal necrolysis to interferon alpha or any other products componentXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipientsXx_NEWLINE_xXPrevious serious hypersensitivity reaction to monoclonal antibodies. (Determination of \serious\ hypersensitivity reaction is at the investigator's discretion.)Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK1120212 and GSK2141795, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or topotecanXx_NEWLINE_xXKnown hypersensitivity to pembrolizumab or another mAb.Xx_NEWLINE_xXKnown hypersensitivity to both allopurinol and rasburicaseXx_NEWLINE_xXHistory of hypersensitivity to any compound in the tetracycline antibiotics groupXx_NEWLINE_xXSteroids for the treatment of hypersensitivity or transfusion reactions.Xx_NEWLINE_xXClinically significant known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study treatment, or excipients, or to dimethyl sulfoxide (structural component of dabrafenib).Xx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the product.Xx_NEWLINE_xXPrior grade 3 hypersensitivity to cetuximab requiring discontinuation\r\n* An exception is for a patient who could subsequently receive cetuximab without a reaction.Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHas a known hypersensitivity, intolerability or contraindication to any component of study treatment, including premedicationXx_NEWLINE_xXKnown prior or suspected hypersensitivity to investigational products.Xx_NEWLINE_xXPrior history of infusion reactions or hypersensitivity to any of the study drugsXx_NEWLINE_xXParticipants who have known hypersensitivity to any component of loperamide or budesonideXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to enzalutamide or their excipientsXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to pazopanib or topotecan or to their excipientsXx_NEWLINE_xXKnown hypersensitivity reaction to mushroom productsXx_NEWLINE_xXSubjects with known hypersensitivity to any of the components of AG-221.Xx_NEWLINE_xXPatients with a known hypersensitivity to any component of bevacizumab are not eligible for participationXx_NEWLINE_xXKnown hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus, deforolimus)Xx_NEWLINE_xXPatients with a known hypersensitivity to tacrolimusXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXKnown hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXPatient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXPatient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.Xx_NEWLINE_xXPatients with a known hypersensitivity to BKM120 or to its excipients, or hypersensitivity to cetuximabXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXKnown anaphylactic or severe hypersensitivity to the study drugs or their analogsXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipientsXx_NEWLINE_xXHistory of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the productXx_NEWLINE_xXPatients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to bevacizumabXx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXKnown allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelixXx_NEWLINE_xXHistory of hypersensitivity to ipilimumabXx_NEWLINE_xXKnown anaphylactic or severe hypersensitivity to dasatinib or crizotinib or their analogsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocolXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHypersensitivity to one of the trial drugs or the excipients.Xx_NEWLINE_xXKnown hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.Xx_NEWLINE_xXKnown hypersensitivity to protein bound paclitaxelXx_NEWLINE_xXKnown hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin).Xx_NEWLINE_xXKnown severe hypersensitivity to tadalafil or any of the excipients of this productXx_NEWLINE_xXHypersensitivity to cytarabine, daunorubicin or liposomal productsXx_NEWLINE_xXKnown or suspected hypersensitivity to the excipients contained in the study drug formulation.Xx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXPatients with known hypersensitivity to rapamycinsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or to recombinant human or murine antibodies, or any of the treatments in this protocolXx_NEWLINE_xXNo known hypersensitivity to 4-aminoquinoline compoundXx_NEWLINE_xXNo known prior hypersensitivity to carboplatin, paclitaxel, bevacizumab or hydroxychloroquine or any of their componentsXx_NEWLINE_xXHypersensitivity to the active substance or to any of the excipients for study drug BT062, or history of severe allergic or anaphylactic reaction to therapeutic proteins (e.g. reaction to vaccination or to biological therapy)Xx_NEWLINE_xXPatients with hypersensitivity to any tetracyclinesXx_NEWLINE_xXKnown hypersensitivity to any components of the treatmentsXx_NEWLINE_xXPatients with a known hypersensitivity to any of the components of the drug productsXx_NEWLINE_xXPatients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).Xx_NEWLINE_xXKnown hypersensitivity reaction or idiosyncrasy to erlotinibXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus (RAD001) or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXKnown anaphylactic or severe hypersensitivity to study drugs or their analogsXx_NEWLINE_xXKnown or suspected hypersensitivity to 5-azacitidine, romidepsin, mannitol or other agents used in this studyXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXNo known hypersensitivity to murine productsXx_NEWLINE_xXNo known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocolXx_NEWLINE_xXKnown hypersensitivity to capecitabine, temozolomide, or any component of the formulation and or a known deficiency of dihydropyrimidine dehydrogenaseXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXThe patient has known hypersensitivity to bovine proteinsXx_NEWLINE_xXHypersensitivity to one or more of the TL-118 active componentsXx_NEWLINE_xXPatients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oilXx_NEWLINE_xXHypersensitivity to propranolol, or beta-blockersXx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXHistory of hypersensitivity reactions to any components of the treatment regimenXx_NEWLINE_xXPatients with a known hypersensitivity to any excipient contained in the drug formulationXx_NEWLINE_xXKnown hypersensitivity to thalidomide.Xx_NEWLINE_xXKnown hypersensitivity to any component of the trial agentsXx_NEWLINE_xXA history of ataxia telangiectasia or other documented history of radiation hypersensitivityXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXKnown hypersensitivity to any component of the formulationXx_NEWLINE_xXAny known hypersensitivity to ofatumumab or its components.Xx_NEWLINE_xXHypersensitivity to acyclovir or similar anti-viral drugXx_NEWLINE_xXHypersensitivity to boron or mannitol, or compounds containing these componentsXx_NEWLINE_xXKnown hypersensitivity to cetuximab or other EGFR antibodyXx_NEWLINE_xXPatients with a history of severe hypersensitivity reaction to JEVTANA (cabazitaxel) or other drugs formulated with polysorbate 80Xx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to any of the study agents usedXx_NEWLINE_xXHistory of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXKnown hypersensitivity to any of the study agentsXx_NEWLINE_xXPatients with known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation that includes trehalose, sodium citrate, and polysorbate 80Xx_NEWLINE_xXKnown hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymyxin B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeastXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitolXx_NEWLINE_xXPatient has known hypersensitivity to the components of study drug or its analogsXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXPatients with a known hypersensitivity to vinorelbine or to its excipientsXx_NEWLINE_xXKnown hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodiesXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulationXx_NEWLINE_xXKnown hypersensitivity to fluoropyrimidines or cisplatin.Xx_NEWLINE_xXPatients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXKnown hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide long-acting release [LAR] formulationsXx_NEWLINE_xXHistory of hypersensitivity to sirolimusXx_NEWLINE_xXHistory of hypersensitivity to vorinostatXx_NEWLINE_xXHistory of hypersensitivity to hydroxychloroquineXx_NEWLINE_xXHistory of hypersensitivity to any component of the formulationXx_NEWLINE_xXPrior carboplatin or cisplatin hypersensitivity reactionXx_NEWLINE_xXFor Part C, have a known hypersensitivity to sorafenib or its excipientsXx_NEWLINE_xXPatient has known hypersensitivity to thalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXPatients with a known hypersensitivity to any of the components of the drug productsXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXHistory of hypersensitivity to bevacizumab or murine products, temsirolimus or its metabolites, or any component of the formulationXx_NEWLINE_xXCARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulationXx_NEWLINE_xXPACLITAXEL ARM: hypersensitivity to paclitaxel or any component of the formulationXx_NEWLINE_xXSORAFENIB ARM: history of hypersensitivity to sorafenib or any component of the formulationXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or everolimus (such as sirolimus or temsirolimus)Xx_NEWLINE_xXEXPANSION COHORT ONLY: Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or everolimus (such as sirolimus or temsirolimus)Xx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXAny history of adverse reaction or hypersensitivity to LDACXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or eribulinXx_NEWLINE_xXKnown intolerance to either of the study drugs (or any of the excipients)Xx_NEWLINE_xXHas severe hypersensitivity (? Grade 3) to any study treatment (pembrolizumab, cisplatin, or 5-FU) and/or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of hypersensitivity to durvalumab, tremelimumab or any excipientXx_NEWLINE_xXKnown hypersensitivity to any components of pracinostat, azacitidine, or mannitolXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE grade ?3), any history of anaphylaxis, or uncontrolled asthma (i.e., ?3 features of partly controlled asthma).Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHas a history of a severe hypersensitivity reaction to treatment with another monoclonal antibodyXx_NEWLINE_xXHas severe hypersensitivity (Grade ?3) to pembrolizumab and/or any of its excipientsXx_NEWLINE_xXKnown history of hypersensitivity to aromatase-inhibitor drugsXx_NEWLINE_xXPatients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.Xx_NEWLINE_xXHas a known hypersensitivity to the components of the study treatment or its analogs.Xx_NEWLINE_xXPrior treatment with or have known hypersensitivity to AL3818.Xx_NEWLINE_xXb. Indication B- LMS: Prior treatment with or have known hypersensitivity to dacarbazine.Xx_NEWLINE_xXc. Indication C - SS: Prior treatment with or have known hypersensitivity to dacarbazine.Xx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to tremelimumabXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to TRC253 or its excipients.Xx_NEWLINE_xXHas known hypersensitivity to baker's yeastXx_NEWLINE_xXHas hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to GM-CSF, yeast-derived products or any component of the GM-CSF drug product (e.g., mannitol) or poly-ICLC (e.g., carboxymethylcellulose).Xx_NEWLINE_xXKnown hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.Xx_NEWLINE_xXKnown hypersensitivity to any component of the investigational product (PVX-410, durvalumab, or any excipient)Xx_NEWLINE_xXKnown intolerance to any of the study drugs (or any of the excipients)Xx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumab and osimertinibXx_NEWLINE_xXHistory of hypersensitivity to bevacizumab, murine products, or any component of the formulationXx_NEWLINE_xXHistory of hypersensitivity to gemcitabineXx_NEWLINE_xXHistory of hypersensitivity to nab-paclitaxel or paclitaxelXx_NEWLINE_xXKnown hypersensitivity to sirolimus.Xx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodiesXx_NEWLINE_xXPatients with known hypersensitivity to any component of bevacizumabXx_NEWLINE_xXPatient has a known hypersensitivity to the components of study drugs, its analogues, or drugs of similar chemical or biologic compositionXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXKnown hypersensitivity to bevacizumab, Chinese hamster ovary cell products, or other recombinant human or humanized antibodiesXx_NEWLINE_xXHypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXPatients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80Xx_NEWLINE_xXNo history of hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXHistory of Grade ? 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophenXx_NEWLINE_xXKnown hypersensitivity to nab-paclitaxel or to gemcitabine or to any of the excipients.Xx_NEWLINE_xXSubject has known history of serious hypersensitivity reaction to a known ingredient of ASP8273, erlotinib or gefitinib.Xx_NEWLINE_xXPrior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in classXx_NEWLINE_xXHistory of Grade ?3 infusion-related adverse events (AEs) or hypersensitivity to NEOD001Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO) or GSK2141795Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXSevere hypersensitivity reaction to treatment with another monoclonal antibody, known or suspected hypersensitivity to study drugs or any component of their formulation.Xx_NEWLINE_xXHistory of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodiesXx_NEWLINE_xXKnown history of ? Grade 3 hypersensitivity to a therapeutic antibody.Xx_NEWLINE_xXHypersensitivity to pembrolizumab, imatinib, or any of its excipientsXx_NEWLINE_xXHas had a severe hypersensitivity reaction to treatment with another monoclonal antibodyXx_NEWLINE_xXPrior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), or ruxolitinib, or any of their excipients.Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2879552 or LSD1 inhibitors that contraindicates their participation.Xx_NEWLINE_xXKnown hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucilXx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXHistory of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI; hypersensitivity skin test is required at screening to rule out allergy to S. cerevisiaeXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXHistory of hypersensitivity to the combination or comparator agentXx_NEWLINE_xXKnown hypersensitivity to filgrastim or to Escherichia coli (E. coli) derived proteinsXx_NEWLINE_xXSubject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.Xx_NEWLINE_xXKnown hypersensitivity to any constituent of the study medication.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of hypersensitivity to polysorbate 80Xx_NEWLINE_xXKnown hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cellsXx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXHypersensitivity to polysorbate 80Xx_NEWLINE_xXKnown hypersensitivity to idelalisib, its metabolites, or formulation excipientsXx_NEWLINE_xXKnown hypersensitivity to nab-paclitaxel (Arm: idelalisib + nab-paclitaxel), their metabolites, or formulation excipientsXx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil, leucovorin, or oxaliplatin (Arm: idelalisib + mFOLFOX6), their metabolites, or formulation excipientsXx_NEWLINE_xXKnown hypersensitivity to any component of recombinant protein production by CHO cellsXx_NEWLINE_xXSubject has a known or suspected hypersensitivity to enzalutamide or any components of the formulation used.Xx_NEWLINE_xXHistory of hypersensitivity to 4-aminoquinoline compoundXx_NEWLINE_xXKnown hypersensitivity to mannitolXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to any of the other study drugsXx_NEWLINE_xXKnown hypersensitivity to the trial drugs, to their excipients or to contrast mediaXx_NEWLINE_xXHistory of allergic reactions to monoclonal antibody therapy (or excipients in the formulation)Xx_NEWLINE_xXKnown hypersensitivity to rituximabXx_NEWLINE_xXHistory of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)Xx_NEWLINE_xXKnown hypersensitivity to any of the components of RO6927005Xx_NEWLINE_xXPatients with contra-indication and/or history of severe hypersensitivity reactions to gemcitabine and/or nab-paclitaxel as mentioned in the locally approved labelXx_NEWLINE_xXPatients with a known hypersensitivity to buparlisib or to its excipientsXx_NEWLINE_xXHypersensitivity to erlotinib, crizotinib or to any of the excipientsXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel, including polyethoxylated castor oil, alcohol, or their excipientsXx_NEWLINE_xXKnown hypersensitivity to afatinib (BIBW 2992) or the excipients of any of the trial drugsXx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to crizotinibXx_NEWLINE_xXKnown hypersensitivity to 5-azacytidine\r\n* Prior treatment with 5-azacytidine is allowedXx_NEWLINE_xXA history of a severe hypersensitivity reaction to ipilimumab or dabrafenibXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or its excipient, or azacitidine, that contraindicates the subjects' participationXx_NEWLINE_xXHistory of hypersensitivity to any of the study drugs or to any excipients.Xx_NEWLINE_xXPrior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), ruxolitinib, or any of their excipients.Xx_NEWLINE_xXKnown hypersensitivity to dacarbazine (DTIC).Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXPatients with known hypersensitivity to any components of ME-344 or topotecan study drug productXx_NEWLINE_xXAny known hypersensitivity or contraindication to the components of study treatmentXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or their excipients.Xx_NEWLINE_xXHistory of iodine hypersensitivityXx_NEWLINE_xXPatients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compoundsXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXKnown hypersensitivity to any inactive ingredient of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to any inactive ingredient of TPI 287Xx_NEWLINE_xXHypersensitivity to tea products or any of the inactive ingredients found in the drug product capsulesXx_NEWLINE_xXKnown hypersensitivity to recombinant proteins, or any component contained in the drug formulationXx_NEWLINE_xXPatients with any known contraindication to treatment with, including hypersensitivity to quinacrine or erlotinibXx_NEWLINE_xXKnown hypersensitivity to lithium or tretinoinXx_NEWLINE_xXKnown hypersensitivity to bevacizumab or any of its excipients or any other study drugXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.Xx_NEWLINE_xXPatient has hypersensitivity to any of the components of study drugs.Xx_NEWLINE_xXKnown or suspected history of severe hypersensitivity reaction to tyrosine kinase inhibitors, histone deacetylase inhibitors, proteosome inhibitors, boron, or mannitolXx_NEWLINE_xXHas a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab;Xx_NEWLINE_xXHas a known hypersensitivity to baker's yeast or has an active yeast infection;Xx_NEWLINE_xXPatients with known hypersensitivity to any of the components of AN-152 including doxorubicin and LH-RH agonistsXx_NEWLINE_xXHistory of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoidXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXSubjects with known hypersensitivity to any components of ALKS 4230Xx_NEWLINE_xXSubjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)Xx_NEWLINE_xXPatients with hypersensitivity to amiodarone or NACXx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of it's excipients.Xx_NEWLINE_xXPatient must not have known sensitivity to terameprocol or any formulation excipientsXx_NEWLINE_xXHypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.Xx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHypersensitivity to obinutuzumabXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs involvedXx_NEWLINE_xXKnown hypersensitivity to thalidomide or other immunomodulatory drugs.Xx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients, or to bortezomib, boron, or mannitolXx_NEWLINE_xXKnown severe hypersensitivity to ketoconazole, calcitriol or any of the excipients of these productsXx_NEWLINE_xXPatients with known hypersensitivity or intolerance to melphalanXx_NEWLINE_xXKnown hypersensitivity to any component of study treatments that resulted in drug discontinuationXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipientsXx_NEWLINE_xXPatient has a known hypersensitivity to dimethyl sulfoxide (DMSO) or murine or bovine proteins.Xx_NEWLINE_xXPrior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.Xx_NEWLINE_xXKnown hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this studyXx_NEWLINE_xXPatients with known prior severe hypersensitivity reactions to cabazitaxel or other agents containing polysorbate 80Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of PQR309.Xx_NEWLINE_xXKnown hypersensitivity to any of the treatment components of ramucirumab or LY2875358.Xx_NEWLINE_xXPrior hypersensitivity to monoclonal antibodiesXx_NEWLINE_xXHypersensitivity to PEG or other component of AEB1102 (Co-ArgI-PEG)Xx_NEWLINE_xXHistory of serious allergic reaction to yeast or yeast-derived products, including known or suspected hypersensitivity reaction to sargramostim;Xx_NEWLINE_xXSubjects with porphyria’s or known hypersensitivity to porphyrinsXx_NEWLINE_xXKnown hypersensitivity to any component of atezolizumab formulation or other study medicationXx_NEWLINE_xXHypersensitivity/infusion reaction to monoclonal antibodies, other therapeutic proteins, or allergy to any component/excipient of FS102 finished drug product (arginine, glycine, phosphoric acid, or polysorbate 80) and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as anti-histamines, 5-HT3 antagonists, or corticosteroids.Xx_NEWLINE_xXKnown hypersensitivity to any component of study treatmentsXx_NEWLINE_xXKnown hypersensitivity to any component of study treatmentsXx_NEWLINE_xXKnown anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab (Rituxan®)Xx_NEWLINE_xXKnown hypersensitivity to bendamustine or mannitolXx_NEWLINE_xXKnown hypersensitivity to the components of niraparibXx_NEWLINE_xXKnown hypersensitivity to bevacizumab or any component of its formulationXx_NEWLINE_xXPatient has a known hypersensitivity to any of the components of the study drug.Xx_NEWLINE_xXPrior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXPrior anaphylactic or severe hypersensitivity reaction to paclitaxel or Cremophor-containing agent.Xx_NEWLINE_xXKnown hypersensitivity to any involved study drug or any of its formulation componentsXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study agents or their excipients that, in the opinion of the Investigator or GSK medical monitor , contra-indicates participationXx_NEWLINE_xXNo known hypersensitivity to trastuzumab or pertuzumabXx_NEWLINE_xXKnown hypersensitivity or intolerance to any of the active substances or excipients in the formulations for ENTOXx_NEWLINE_xXHave known allergies, hypersensitivity, or intolerance to enzalutamide or niclosamide or their excipientsXx_NEWLINE_xXA history of heparin-induced thrombocytopenia or hypersensitivity to heparin, enoxaparin, or pork productsXx_NEWLINE_xXHistory of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates)Xx_NEWLINE_xXKnown hypersensitivity to rosuvastatinXx_NEWLINE_xXSubject has a known history of serious hypersensitivity to ASP2215, or any component of the formulation used.Xx_NEWLINE_xXKnown hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipientsXx_NEWLINE_xXHistory of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugsXx_NEWLINE_xXSevere allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of the study drugsXx_NEWLINE_xXKnown allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.Xx_NEWLINE_xXKnown hypersensitivity or intolerance to metforminXx_NEWLINE_xXThe subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;Xx_NEWLINE_xXKnown hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXKnown hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this studyXx_NEWLINE_xXKnown hypersensitivity to HDAC inhibitors or to any of the components of mocetinostatXx_NEWLINE_xXKnown hypersensitivity to gemcitabineXx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to polysorbate 80Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine phosphate (fludarabine)Xx_NEWLINE_xXKnown hypersensitivity to any of the components of AG-221Xx_NEWLINE_xXPatients in the combination arms - known hypersensitivity to fulvestrantXx_NEWLINE_xXHypersensitivity to cytarabine, daunorubicin or liposomal productsXx_NEWLINE_xXKnown hypersensitivity to afatinib, monoclonal antibodyXx_NEWLINE_xXKnown intolerance of or hypersensitivity to fosbretabulinXx_NEWLINE_xXKnown hypersensitivity or history of severe intolerance or toxicity to study-assigned chemotherapy. Note: History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for participants to be treated with MLN4924 + docetaxel; history of hypersensitivity to carboplatin for participants to be treated with MLN4924 + carboplatin + paclitaxel; or history of severe hypersensitivity to paclitaxel (Cremophor-based formulations) for participants to be treated with MLN4924 + carboplatin + paclitaxel in Part B.Xx_NEWLINE_xXKnown hypersensitivity to filgrastim, plerixafor, or Escherichia (E.) coli derived productsXx_NEWLINE_xXKnown hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4 infusion related reactions with anti-EGFR mABsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to dabrafenib, rosuvastatin, and midazolam, or excipients that contraindicate their participation; or have an allergy to cherries.Xx_NEWLINE_xXKnown hypersensitivity to thalidomide or Revlimid (if applicable)Xx_NEWLINE_xXKnown hypersensitivity to any component of study treatments that resulted in drug discontinuationXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).Xx_NEWLINE_xXNo prior history of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinuedXx_NEWLINE_xXHistory of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)Xx_NEWLINE_xXKnown hypersensitivity to any components of the study drugsXx_NEWLINE_xXHave known hypersensitivity to platinum (Pt) compoundsXx_NEWLINE_xXHistory of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapyXx_NEWLINE_xXKnown hypersensitivity or contraindication to study drugs, oxazolidinones, or quinolones.Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, GSK2141795, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2118436 or excipients that contraindicate their participationXx_NEWLINE_xXKnown hypersensitivity to any component of study treatmentsXx_NEWLINE_xXHistory of hypersensitivity to hydrogelXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxelXx_NEWLINE_xXKnown hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this studyXx_NEWLINE_xXHypersensitivity to recombinant human IL-2Xx_NEWLINE_xXKnown hypersensitivity to carfilzomibXx_NEWLINE_xXHistory of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapyXx_NEWLINE_xXPatients with a known or suspected hypersensitivity to any of the components of OTS167.Xx_NEWLINE_xXKnown hypersensitivity to any components of SC16LD6.5 study drug product.Xx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXKnown hypersensitivity to any of the study drugs or its excipients.Xx_NEWLINE_xXType I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusion of rituximabXx_NEWLINE_xXKnown hypersensitivity to Tween-80, or human immunoglobulinXx_NEWLINE_xXKnown hypersensitivity to chlorambucil or any of its excipientsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drugs (GSK3052230, docetaxel, paclitaxel, carboplatin, pemetrexed, cisplatin) and or their excipients that contraindicate their participation.Xx_NEWLINE_xXKnown hypersensitivity to study-assigned chemotherapyXx_NEWLINE_xXKnown significant hypersensitivity to any components of study treatmentXx_NEWLINE_xXHave known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipientsXx_NEWLINE_xXKnown hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulationXx_NEWLINE_xXHistory of intolerance (including grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab or murine proteinsXx_NEWLINE_xXKnown hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXKnown hypersensitivity to compounds related to orteronel or to orteronel excipientsXx_NEWLINE_xXHistory of hypersensitivity to amikacin or other aminoglycosidesXx_NEWLINE_xXHistory of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotides.Xx_NEWLINE_xXSubjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX001 or its excipients.Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXSubjects with known hypersensitivity to peptide drugs, including LHRH agonists.Xx_NEWLINE_xXKnown hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cellsXx_NEWLINE_xXPatients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-724.Xx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXHistory of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteinXx_NEWLINE_xXKnown hypersensitivity to any study drugXx_NEWLINE_xXHypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapyXx_NEWLINE_xXHypersensitivity of AT13387 or other components of the drug productXx_NEWLINE_xXKnown hypersensitivity to bortezomib, boron, or mannitolXx_NEWLINE_xXKnown hypersensitivity to BKM120 or to its excipientsXx_NEWLINE_xXKnown hypersensitivity to NSAIDsXx_NEWLINE_xXHistory of hypersensitivity to taxanes or drug formulations containing Cremophor®.Xx_NEWLINE_xXPrior hypersensitivity to bevacizumab or toxicity requiring discontinuation of bevacizumab (Phase I)Xx_NEWLINE_xXPrior hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (Phase I and II)Xx_NEWLINE_xXPrior hypersensitivity to triptan derivatives (Phase I and II)Xx_NEWLINE_xXPatients with known hypersensitivity to sorafenib or any other component of sorafenib.Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2636771or enzalutamide or excipients.Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study treatment or excipients that contraindicate their participation.Xx_NEWLINE_xXKnown or suspected hypersensitivity to 5'-azacitidine or mannitolXx_NEWLINE_xXKnown hypersensitivity to the components of niraparib, PD-1 inhibitor, or their excipientsXx_NEWLINE_xXKnown hypersensitivity to the components of niraparib or excipientsXx_NEWLINE_xXKnown hypersensitivity to the active substance or to any of the excipients in the vaccineXx_NEWLINE_xXPhase 1b and crossover only: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; Known hypersensitivity to Chinese Hamster Ovary (CHO)-cell products; Allergy or hypersensitivity to components of the atezolizumab formulationXx_NEWLINE_xXDocumented allergic or acute hypersensitivity reaction attributed to antibody treatmentsXx_NEWLINE_xXKnown hypersensitivity to any of the components of PRI-724Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to any of the agents used in this studyXx_NEWLINE_xXPatients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXA known hypersensitivity to metforminXx_NEWLINE_xXPatients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.Xx_NEWLINE_xXPatients with a known hypersensitivity to any of the components of the drug productsXx_NEWLINE_xXKnown hypersensitivity to vareniclineXx_NEWLINE_xXPatients with known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipientsXx_NEWLINE_xXKnown hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulationXx_NEWLINE_xXHistory of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)Xx_NEWLINE_xXKnown hypersensitivity to thalidomideXx_NEWLINE_xXPatient has hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXKnown unmanageable allergies, hypersensitivity, intolerance to monoclonal antibodies, to murine, chimeric, human proteins or their excipientsXx_NEWLINE_xXKnown hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseenXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine, dexamethasone, or their excipientsXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to dacarbazine does not applyXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.Xx_NEWLINE_xXHypersensitivity to the active substance, or any of the excipients of the eribulin drug product, or dacarbazine, (please refer to the dacarbazine prescribing information).Xx_NEWLINE_xXHistory of hypersensitivity reaction to human or mouse antibody productsXx_NEWLINE_xXKnown hypersensitivity to the study drugsXx_NEWLINE_xXKnown hypersensitivity to the study drugsXx_NEWLINE_xXPatients with a known hypersensitivity to BKM120 or to its excipientsXx_NEWLINE_xXKnown or suspected hypersensitivity to ofatumumab, bendamustine or mannitol.Xx_NEWLINE_xXKnown hypersensitivity to thalidomide or everolimus (including other rapamycins, sirolimus and temsirolimus)Xx_NEWLINE_xXHistory of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapyXx_NEWLINE_xXSuspected hypersensitivity to interferon alphaXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies including hypersensitivity to any component of bevacizumabXx_NEWLINE_xXKnown history of dose-limiting hypersensitivity reactions to paclitaxel/Cremophor ELXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanibXx_NEWLINE_xXA history of a severe hypersensitivity reaction to nab-paclitaxelXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs or excipients.Xx_NEWLINE_xXKnown hypersensitivity to polymyxin BXx_NEWLINE_xXHistory of severe hypersensitivity reaction to drugs formulated with polysorbate 80Xx_NEWLINE_xXKnown significant hypersensitivity to study drugs or excipientsXx_NEWLINE_xXHypersensitivity to trial medicationsXx_NEWLINE_xXKnown hypersensitivity to bendamustine, mannitol, or other study-related drugsXx_NEWLINE_xXPatients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipientsXx_NEWLINE_xXHypersensitivity to azacitidine or mannitolXx_NEWLINE_xXKnown hypersensitivity to other Src/Abl non-receptor kinase inhibitors.Xx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine or mannitolXx_NEWLINE_xXKnown severe hypersensitivity to or any of the excipients of this product.Xx_NEWLINE_xXHistory of allergies or known hypersensitivity to any components of melphalan or the components of the Melphalan/HDS systemXx_NEWLINE_xXKnown hypersensitivity to heparin or the presence of heparin-induced thrombocytopeniaXx_NEWLINE_xXHypersensitivity to cytarabine, daunorubicin or liposomal productsXx_NEWLINE_xXKnown hypersensitivity to any of the study drugsXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, emactuzumab formulation, or obinutuzumab formulationXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of hypersensitivity reactions attributed to simvastatinXx_NEWLINE_xXHistory of hypersensitivity to durvalumab or any excipientXx_NEWLINE_xXKnown hypersensitivity to ibrutinib or nivolumabXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to sirolimusXx_NEWLINE_xXHistory of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)Xx_NEWLINE_xXSubject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.Xx_NEWLINE_xXKnown hypersensitivity to BGJ398, fluorouracil, oxaliplatin, irinotecan or to any of the excipientsXx_NEWLINE_xXKnown hypersensitivity to any of the components of talazoparibXx_NEWLINE_xXKnown hypersensitivity to any component of RDHAPXx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine (fludarabine phosphate)Xx_NEWLINE_xXHistory of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabineXx_NEWLINE_xXPatients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compoundsXx_NEWLINE_xXKnown hypersensitivity to human albuminXx_NEWLINE_xXHave known hypersensitivity to pancuronium bromide, atracurium or cisatracurium,Xx_NEWLINE_xXHave known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents,Xx_NEWLINE_xXPatient has a known hypersensitivity to any of the excipients of BKM120Xx_NEWLINE_xXKnown hypersensitivity to metformin or statinsXx_NEWLINE_xXNo known serious or severe hypersensitivity reaction to naloxegol or any of its excipientsXx_NEWLINE_xXHave a known hypersensitivity to olanzapine or to phenothiazinesXx_NEWLINE_xXHistory of hypersensitivity to other psychostimulantsXx_NEWLINE_xXPatients known to have hypersensitivity to dacarbazine (DTIC) are not eligibleXx_NEWLINE_xXKnown allergic reaction to nickelXx_NEWLINE_xXKnown hypersensitivity to somatostatin analogs or any component of the pasireotide long acting release (LAR) or suspension concentrate (s.c.) formulationsXx_NEWLINE_xXHave known hypersensitivity to anthracycline compounds or any excipient in NC-6300.Xx_NEWLINE_xXKnown hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;Xx_NEWLINE_xXHas a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXKnown or suspected hypersensitivity to any of the talazoparib capsule components.Xx_NEWLINE_xXKnown or suspected hypersensitivity to any of the talazoparib capsule components.Xx_NEWLINE_xXKnown hypersensitivity (example, anaphylactic and anaphylactoid reactions) to any particular combination drug will result in a participant being ineligible for inclusion in that particular cohort.Xx_NEWLINE_xXHas hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other mAbs.Xx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinXx_NEWLINE_xXKnown hypersensitivity to any component of the atezolizumab productXx_NEWLINE_xXHistory of severe hypersensitivity to monoclonal antibodies.Xx_NEWLINE_xXHistory of severe hypersensitivity to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.Xx_NEWLINE_xXKnown hypersensitivity to coldXx_NEWLINE_xXHistory hypersensitivity to opioids.Xx_NEWLINE_xXPatient with known hypersensitivity to rocuronium, sugammadex or its components.Xx_NEWLINE_xXHistory of hypersensitivity or reaction to N-methyl-D-aspartate (NMDA) receptor antagonistsXx_NEWLINE_xXPrior carboplatin or oxaliplatin hypersensitivity reactionXx_NEWLINE_xXPatient has a history of hypersensitivity to fentanyl or opioidsXx_NEWLINE_xXMajor contraindications to anamorelin e.g. hypersensitivityXx_NEWLINE_xXPATIENTS: History of hypersensitivity to haloperidol or chlorpromazineXx_NEWLINE_xXPatients with a known hypersensitivity reaction to 5-HT3 receptor antagonists or NK1 receptor antagonistsXx_NEWLINE_xXKnown hypersensitivity reaction to any component of ferric carboxymaltoseXx_NEWLINE_xXHypersensitivity to JAK inhibitorsXx_NEWLINE_xXPatients with hypersensitivity to ropivacaine/amide-type anestheticsXx_NEWLINE_xXPatient has a known hypersensitivity to the administration of any prescribed oral or intravenous study medication or metabolite, including but not limited to, a history of hypersensitivity to the drugs or their components, severe renal impairment, severe bone marrow suppression, or systemic infectionXx_NEWLINE_xXPatients with a history of hypersensitivity to dexamethasone or having any contraindication to physical activity as determined by the treating physicianXx_NEWLINE_xXHypersensitivity to pregabalinXx_NEWLINE_xXHistory of hypersensitivity to pregabalin or gabapentinXx_NEWLINE_xXHistory of hypersensitivity or severe intolerance to azolesXx_NEWLINE_xXA known immediate or delayed hypersensitivity reaction or idiosyncrasy that, in the opinion of the Medical Monitor is due to drugs chemically related to eltrombopag or excipients (e.g. mannitol)Xx_NEWLINE_xXMajor contraindication to methylphenidate i.e. hypersensitivityXx_NEWLINE_xXHypersensitivity to ginsengXx_NEWLINE_xXPatients with known hypersensitivity to octreotide or somatostatinXx_NEWLINE_xXPatients with known hypersensitivity to NT-I7 or any component used in the vehicle/formulation are ineligibleXx_NEWLINE_xXPatients with a history of echinocandin or fluconazole hypersensitivity are not eligibleXx_NEWLINE_xXPatients with a history of echinocandin or azole hypersensitivity are not eligibleXx_NEWLINE_xXParticipants with known hypersensitivity to modafinil, armodafinil, or any of its componentsXx_NEWLINE_xXKnown hypersensitivity to any component of bevacizumabXx_NEWLINE_xXKnown hypersensitivity to any component of testosteroneXx_NEWLINE_xXHistory of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinoloneXx_NEWLINE_xXSevere hypersensitivity reaction to apixaban, dalteparin, heparin or pork products (e.g., anaphylactic reactions)Xx_NEWLINE_xXKnown or suspected hypersensitivity or intolerance to fentanyl or hydromorphone or excipients in the study medicationsXx_NEWLINE_xXKnown or suspected hypersensitivity to any of the constituents of the investigational productXx_NEWLINE_xXKnown hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant human antibodiesXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of hypersensitivity to any excipients in the quizartinib/placebo tablets;Xx_NEWLINE_xXKnown hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009Xx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies.Xx_NEWLINE_xXPatients with known hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to ASN002 or its excipients;Xx_NEWLINE_xXPrior history of hypersensitivity to milk proteinsXx_NEWLINE_xXPatients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis or any other serious adverse reaction to any of the anesthetics or analgesics medications used in the studyXx_NEWLINE_xXPatients with hypersensitivity to any tetracyclineXx_NEWLINE_xXAny known hypersensitivity to dexmedetomidineXx_NEWLINE_xXHistory of hypersensitivity to haloperidol or benzodiazepineXx_NEWLINE_xXHypersensitivity to any tetracycline, or a history of other allergies or drug reactions that in the treating physician's judgment make the patient inappropriate for this studyXx_NEWLINE_xXPatients with hypersensitivity to tetracyclinesXx_NEWLINE_xXMinocycline trial only: patients with hypersensitivity to any tetracyclinesXx_NEWLINE_xXPatients with previous history of hypersensitivity to ribavirin or its componentsXx_NEWLINE_xXKnown hypersensitivity or intolerance to metforminXx_NEWLINE_xXNo history of severe hypersensitivity reactions to drugs or other causes (e.g., beestings)Xx_NEWLINE_xXKnown hypersensitivity to recombinant ESAs or the excipients contained within the investigational product.Xx_NEWLINE_xXHypersensitivity to dexamethasone or corticosteroids or Equal sugar substituteXx_NEWLINE_xXPatients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to the medication used in the studyXx_NEWLINE_xXHistory of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational productXx_NEWLINE_xXPatients with known hypersensitivity to sildenafil or other ingredients of sildenafilXx_NEWLINE_xXPatient with known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extractsXx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or excipient that contraindicates the patients' participationXx_NEWLINE_xXKnown hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast mediaXx_NEWLINE_xXSubjects with a history of hypersensitivity or idiosyncratic reactions to azole agentsXx_NEWLINE_xXHistory of hypersensitivity to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LumasonXx_NEWLINE_xXPrevious documented history of moderate to severe hypersensitivity to Gd contrast agentsXx_NEWLINE_xXDocumented hypersensitivity to any component of ranolazine (Ranexa) pillsXx_NEWLINE_xXPrevious medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.Xx_NEWLINE_xXPatients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts; patients must not have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal antiinflammatory drugs (NSAIDs)Xx_NEWLINE_xXContraindication to metformin prevention such as acute hypersensitivity or allergic reaction to metforminXx_NEWLINE_xXPatient has a known history of hypersensitivity to defibrotide or any of the excipients.Xx_NEWLINE_xXSevere hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)Xx_NEWLINE_xXHistory of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg proteinXx_NEWLINE_xXHistory of known latex hypersensitivityXx_NEWLINE_xXKnown hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)Xx_NEWLINE_xXHistory of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg proteinXx_NEWLINE_xXHistory of known latex hypersensitivityXx_NEWLINE_xXPatients with a known hypersensitivity to GM-CSF, yeast-derived products, or any component of the GM-CSF product (e.g., mannitol)Xx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to any of the study medications.Xx_NEWLINE_xXHistory of hypersensitivity or idiosyncratic reactions to azolesXx_NEWLINE_xXPatient has a known hypersensitivity to the administration of rolapitant or its excipientsXx_NEWLINE_xXKnown hypersensitivity to NACXx_NEWLINE_xXHistory of hypersensitivity or allergic reaction to NRT, or any component of its formulationXx_NEWLINE_xXPatients who have hypersensitivity to sitagliptinXx_NEWLINE_xXHistory of hypersensitivity reactions to murine protein-containing productsXx_NEWLINE_xXHistory of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulationsXx_NEWLINE_xXKnown hypersensitivity to cyclophosphamide or any of its metabolitesXx_NEWLINE_xXHistory of hypersensitivity to COX-2 inhibitors, sulfonamides, nonsteroidal antiinflammatory drugs (NSAIDs), salicylates, or ursodeoxycholic acidXx_NEWLINE_xXKnown hypersensitivity to one or more of the study agentsXx_NEWLINE_xXKnown hypersensitivity to any component of the MPDL3280A or rociletinib formulations or history or hypersensitivity to chimeric humanized antibodies or fusion proteinsXx_NEWLINE_xXHistory of hypersensitivity reaction to Xolair or any ingredient of XolairXx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibodyXx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2857916 or any of the components of the study treatment.Xx_NEWLINE_xXHave a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO) or to either carboplatin or paclitaxelXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXKnown severe hypersensitivity to paclitaxelXx_NEWLINE_xXHistory of hypersensitivity to durvalumab, tremelimumab or any excipientXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinXx_NEWLINE_xXKnown hypersensitivity to any component of the nivolumab or ipilimumab productXx_NEWLINE_xXHistory of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this StudyXx_NEWLINE_xXHistory of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredientsXx_NEWLINE_xXKnown allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived productsXx_NEWLINE_xXHistory of hypersensitivity to ribociclib or any of its componentsXx_NEWLINE_xXNo known hypersensitivity or intolerance to metforminXx_NEWLINE_xXPatients with hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXPatients with hypersensitivity to bortezomib, boron or mannitolXx_NEWLINE_xXHas suspected or known hypersensitivity to ingredients of MK-8228 (letermovir) formulationsXx_NEWLINE_xXKnown intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);Xx_NEWLINE_xXHistory of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.Xx_NEWLINE_xXHistory of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccineXx_NEWLINE_xXSubjects with a known hypersensitivity to calcitriolXx_NEWLINE_xXHistory of allergic reactions or hypersensitivity to ketamineXx_NEWLINE_xXThe patient has a known hypersensitivity to Lymphazurin or LymphoseekXx_NEWLINE_xXPatients with known or suspected hypersensitivity to perflutrenXx_NEWLINE_xXSubject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure)Xx_NEWLINE_xXHistory of hypersensitivity to Definity (perflutren lipid microsphere) or LumasonXx_NEWLINE_xXHistory of hypersensitivity to iodinated contrast agentXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator’s discretionXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown hypersensitivity to olaparibXx_NEWLINE_xXKnown hypersensitivity to polyethylene glycol (PEG) 300Xx_NEWLINE_xXPatients with hypersensitivity to sonazoid or one of its componentsXx_NEWLINE_xXKnown hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity)Xx_NEWLINE_xXHEALTHY VOLUNTEER: Known hypersensitivity to UCAsXx_NEWLINE_xXHistory of hypersensitivity to nickelXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator’s discretionXx_NEWLINE_xXHypersensitivity to potassium iodide or Lugols productsXx_NEWLINE_xXKnown hypersensitivity to any component of perflutren lipid (Definity)Xx_NEWLINE_xXParticipants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytolXx_NEWLINE_xXHypersensitivity to perflutrenXx_NEWLINE_xXHypersensitivity to the contrast agent 'Definity'Xx_NEWLINE_xXHypersensitivity to iodide productsXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretionXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator’s discretionXx_NEWLINE_xXHypersensitivity to dextran and/or modified form thereofXx_NEWLINE_xXSubjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytolXx_NEWLINE_xXSubjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytolXx_NEWLINE_xXKnown hypersensitivity to perflutren (if the patient has been exposed to perflutren in the past and had an allergic reaction)Xx_NEWLINE_xXPrevious hypersensitivity reaction to LAR octreotideXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretionXx_NEWLINE_xXKnown hypersensitivity to trastuzumab or pertuzumabXx_NEWLINE_xXWomen with known cardiac shunt, pulmonary hypertension or hypersensitivity to perflutren agentXx_NEWLINE_xXPatients with known or suspected hypersensitivity to perflutrenXx_NEWLINE_xXPatients with any known hypersensitivity to perflutren agentXx_NEWLINE_xXPatient must not have a known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodiesXx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugsXx_NEWLINE_xXHypersensitivity to NVB or any of its excipients or to any component of AVD + BV therapyXx_NEWLINE_xXHas a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients.Xx_NEWLINE_xXHistory of severe reactions (e.g. allergic, anaphylactic, or other hypersensitivity) to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXHypersensitivity to CBT-101, excipients of the drug product, or other components of the study treatment regimen.Xx_NEWLINE_xXHistory of severe, immediate hypersensitivity reaction attributed to aminoglycosidesXx_NEWLINE_xXKnown intolerance, hypersensitivity, or contraindication to glucocorticoids.Xx_NEWLINE_xXPatients must not have a hypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown intolerance to pritelivir and/or foscarnet or any of the excipients.Xx_NEWLINE_xXHistory of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014Xx_NEWLINE_xXPatient with a history of severe hypersensitivity reaction to the planned study treatment including gemcitabine, paclitaxel, cisplatin, carboplatin, pemetrexed or any known excipients of these drugsXx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.Xx_NEWLINE_xXKnown prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)Xx_NEWLINE_xXHistory of severe allergic/hypersensitivity reaction or significant transfusion reaction.Xx_NEWLINE_xXKnown hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for enoblituzumabXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity or anaphylactic reaction to any somatostatin analog or to maytansinoidsXx_NEWLINE_xXPatients with known hypersensitivity to any component of Definity micro bubble contrastXx_NEWLINE_xXPatients with history of hypersensitivity reaction to any component of 89Zr-DFO-MSTP2109A, including DFOXx_NEWLINE_xXPatients with known hypersensitivity to perflutrenXx_NEWLINE_xXPatients with a contraindication to having MR imaging (e.g. pacemaker) or contrast MR administration (e.g. hypersensitivity to gadolinium or renal insufficiency above the institutional threshold for administration of contrast); patients with hypersensitivity to MR contrast may be able to participate if it has been established that premedication will mitigate the hypersensitivity reactionXx_NEWLINE_xXKnown hypersensitivity to the study drug or components of the preparationXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals (patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator’s discretion)Xx_NEWLINE_xXWomen with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodidesXx_NEWLINE_xXhistory of hypersensitivity to iodineXx_NEWLINE_xXKnown hypersensitivity to Feraheme (ferumoxytol) or any of its componentsXx_NEWLINE_xXPatients with known hypersensitivity to perflutrenXx_NEWLINE_xXThe subject has a known hypersensitivity to Isosulfan Blue Dye.Xx_NEWLINE_xXSubject has intolerance or hypersensitivity to iron or dextran compounds or to SiennaXP.Xx_NEWLINE_xXKnown or suspected: hypersensitivity to perflutren, blood, blood products or albuminXx_NEWLINE_xXKnown or suspected: hypersensitivity to a prior perflutren protein-type A microspheres (OPTISON) administrationXx_NEWLINE_xXHistory of iodine hypersensitivityXx_NEWLINE_xXAny known hypersensitivity or contraindication to the components of study treatmentXx_NEWLINE_xXPatients with known hypersensitivity to any of the components of PEGPH20 or cetuximab*Xx_NEWLINE_xXKnown hypersensitivity to metforminXx_NEWLINE_xXKnown hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drugXx_NEWLINE_xXEXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drugXx_NEWLINE_xXKnown hypersensitivity to NSAIDsXx_NEWLINE_xXPatients with known hypersensitivity including anaphylaxis to trabectedinXx_NEWLINE_xXKnown hypersensitivity to NSAIDsXx_NEWLINE_xXKnown hypersensitivity or intolerance to itraconazole or similar class agents.Xx_NEWLINE_xXHistory of severe hypersensitivity reactions to other monoclonal antibodies.Xx_NEWLINE_xXKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug, dimethyl sulfoxide (DMSO), or excipientsXx_NEWLINE_xXPatients may not have a known hypersensitivity to any of the components of ganetespibXx_NEWLINE_xXHypersensitivity to Caphosol ingredientsXx_NEWLINE_xXParticipant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in TAK-164 formulation.Xx_NEWLINE_xXKnown hypersensitivity to gemcitabine or any component of the formulation.Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to other monoclonal antibodiesXx_NEWLINE_xXAllergies and Adverse Drug Reaction a. Subjects with known hypersensitivity to excipients of Dasatinib tabletsXx_NEWLINE_xXHypersensitivity to decitabine, SGI-110, or SGI-110 excipients.Xx_NEWLINE_xXThe patient received omacetaxine or has a history of hypersensitivity.Xx_NEWLINE_xXHistory of hypersensitivity to iodine.Xx_NEWLINE_xXHistory of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization.Xx_NEWLINE_xXPatients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate), midazolam and warfarin as described in the local product information.Xx_NEWLINE_xXPatients with a history of hypersensitivity to nickel.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXKnown or suspected hypersensitivity to azacitidine, pembrolizumab or the excipients of any of the study drugs (including mannitol). Known or suspected hypersensitivity to monoclonal antibodies.Xx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXPrior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulationXx_NEWLINE_xXHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteinsXx_NEWLINE_xXKnown hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule.Xx_NEWLINE_xXKnown hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this studyXx_NEWLINE_xXHistory of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to CremophorXx_NEWLINE_xXKnown intolerance to study drug (or any of the excipients).Xx_NEWLINE_xXKnown hypersensitivity to protein bound paclitaxelXx_NEWLINE_xXHas hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab.Xx_NEWLINE_xXKnown history of immunogenicity or hypersensitivity to a CD19 antibody.Xx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xXHypersensitivity to pembrolizumab or any of its excipientsXx_NEWLINE_xX